Modulators of the integrated stress response pathway

A new class of compounds modulating the integrated stress response pathways addresses the need for improved pharmacokinetic properties, effectively treating cancer and neurodegenerative disorders by regulating protein expression and signaling.

JP7588089B2Active Publication Date: 2024-11-21EVOTECH INT GMBH
View PDF 25 Cites 0 Cited by

Patent Information

Application Number
JP2021562991
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-04-23
Filing Date
2020-04-22
Publication Date
2024-11-21
Estimated Expiration
2040-04-22

Smart Images

  • Figure 0007588089000001
    Figure 0007588089000001
  • Figure 0007588089000002
    Figure 0007588089000002
  • Figure 0007588089000003
    Figure 0007588089000003
Patent Text Reader

Abstract

The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates, tautomers or stereoisomers thereof, wherein R 1 From R 3 , A 1 and A 2 has the meaning as indicated in the description and claims. The invention further relates to pharmaceutical compositions comprising said compounds, their use as medicaments and in methods for the treatment and prevention of one or more diseases or disorders associated with the integrated stress response. [Formula 1] TIFF2022530051000048.tif38118
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] The present invention relates to a compound of formula (I) [ka] or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, wherein R 1 From R 3 , A 1 and A 2 has the meaning as indicated in the description and claims. The invention further relates to pharmaceutical compositions comprising said compounds, their use as medicaments and their use in methods for treating and preventing one or more diseases or disorders associated with the integrated stress response. [Background technology]

[0002] The integrated stress response (ISR) is a cellular stress response common to all eukaryotes. (1) Dysregulation of ISR signaling has important pathological consequences, leading to inflammation, viral infections, diabetes, cancer, and neurodegenerative diseases, among others.

[0003] The ISR is a common factor in different types of cellular stress that results in the phosphorylation of the alpha subunit of eukaryotic translation initiation factor 2 (eIF2alpha) on serine 51, leading to the repression of normal protein synthesis and the expression of stress-response genes (2). In mammalian cells, this phosphorylation is carried out by a family of four eIF2alpha kinases, each of which responds to distinct environmental and physiological stresses: PKR-like ER kinase (PERK), double-stranded RNA-dependent protein kinase (PKR), heme-regulated eIF2alpha kinase (HRI), and general control non-derepressible 2 (GCN2) (3).

[0004] eIF2 alpha, together with eIF2 beta and eIF2 gamma, forms the eIF2 complex, a key player in the initiation of normal mRNA translation (4). The eIF2 complex mediates the initiation of mRNA translation by catalyzing GTP and Met-tRNA. i to form the ternary complex (eIF2-GTP-Met-tRNA) that is recruited by the ribosome for translation initiation. i ) to form (5, 6).

[0005] eIF2B is a heterodecameric complex consisting of five subunits (alpha, beta, gamma, delta, and epsilon) that, in duplicate, form a GEF-active decamer ( 7 ).

[0006] In response to ISR activation, phosphorylated eIF2alpha inhibits eIF2B-mediated exchange of GDP for GTP, resulting in reduced ternary complex formation and, therefore, inhibition of translation of normal mRNAs characterized by ribosome binding to the 5' AUG start codon (8). Under these conditions of reduced ternary complex abundance, translation of several specific mRNAs, including the mRNA encoding the transcription factor ATF4, is activated through a mechanism involving altered translation of upstream ORFs (uORFs) (7, 9, 10). These mRNAs typically contain one or more uORFs that function normally in unstressed cells to restrict ribosome flow to the primary coding ORF. For example, under normal conditions, uORFs in the 5' UTR of ATF4 occupy ribosomes and prevent translation of the ATF4 coding sequence. However, under stress conditions, i.e., under conditions of reduced ternary complex formation, the probability that ribosomes will scan past these upstream ORFs and initiate translation at the ATF4-coding ORF is increased. ATF4 and other stress response factors expressed in this manner subsequently direct the expression of an array of additional stress response genes: the acute phase consists in the expression of proteins aimed at restoring homeostasis, while the chronic phase leads to the expression of pro-apoptotic factors (1, 11, 12, 13).

[0007] Upregulation of markers of ISR signaling has been demonstrated in a variety of conditions, including cancer and neurodegenerative diseases. In cancer, ER stress-regulated translation increases resistance to hypoxic conditions and promotes tumor growth (14, 15, 16), and genetic deletion of PERK results in the transformation of PERK. - / - It has been shown to slow the growth of tumors derived from mouse embryonic fibroblasts (14, 17). Furthermore, a recent report provided proof of concept that activators of eIF2B are effective in treating aggressive metastatic forms of prostate cancer using patient-derived xenograft modeling in mice (28). Taken together, prevention of cytoprotective ISR signaling may represent an effective antiproliferative strategy for the treatment of at least some forms of cancer.

[0008] Furthermore, modulation of ISR signaling has proven effective in preserving synaptic function and reducing neuronal loss, as well as in neurodegenerative diseases characterized by activation of the misfolded and unfolded protein response (UPR), such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease (AD), Parkinson's disease (PD), and Jakob-Creutzfeldt disease (prion disease) (18, 19, 20). There are examples of neurodegenerative diseases, such as prion disease, where pharmacological as well as genetic inhibition of ISR signaling has been shown to normalize protein translation levels, rescue synaptic function, and prevent neuronal loss (21). Specifically, reducing the level of phosphorylated eIF2α by overexpressing a phosphatase that controls phosphorylated eIF2α increased the survival time of prion-infected mice, whereas sustained eIF2α phosphorylation decreased survival (22).

[0009] Furthermore, direct evidence for the importance of controlling protein expression levels for proper brain function exists in the form of rare genetic diseases affecting the function of eIF2 and eIF2B. Mutations in eIF2gamma, which disrupt the integrity of the eIF2 complex and therefore result in a reduction of normal protein expression levels, lead to intellectual disability syndrome (ID) (23). Partial loss of function mutations in the eIF2B subunit have been shown to be responsible for the rare leukodystrophy vanishing white matter disease (VWMD) (24, 25). Specifically, stabilization of partial loss of function eIF2B in a VWMD mouse model with a small molecule related to ISRIB has been shown to reduce ISR markers and improve functional as well as pathological endpoints (26, 27).

[0010] Modulators of the eIF2 alpha pathway are described in U.S. Patent No. 6,266,239. U.S. Patent No. 6,266,239, U.S. Patent No. 6,266,239, U.S. Patent No. 6,266,239, and U.S. Patent No. 6,266,239 describe modulators of the integrated stress pathway. U.S. Patent No. 6,266,239, ... and U.S. Patent No. 6,266,239 describe inhibitors of the ATF4 pathway. U.S. Patent No. 6,266,239 and U.S. Patent No. 6,266,239 relate to eukaryotic initiation factor 2B modulators.

[0011] Further documents describing modulators of the integrated stress pathway are U.S. Patent No. 5,623,299, ...

[0012] However, there is a continuing need for new compounds useful as modulators of the integrated stress response pathway that have good pharmacokinetic properties. [Prior art documents] [Patent documents]

[0013]

Patent Document 1

Patent document 2

Patent Document 3

Patent document 4

Patent document 5

Patent document 6

Patent document 7

Patent document 8

Patent document 9

Patent document 10

Patent document 11

Patent document 12

Patent document 13

Patent document 14

Patent document 15

Patent document 16

Patent document 17

Patent document 18

Patent document 19

Patent document 20

[0014] It is therefore an object of the present invention to provide a new class of compounds as modulators of the integrated stress response pathway that may be effective in treating integrated stress response pathway-associated diseases and may have improved pharmaceutically relevant properties, including activity, selectivity, ADMET properties and / or reduced side effects. [Means for solving the problem]

[0015] Thus, the present invention provides a compound of formula (I) [ka] or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, wherein A 1 is a C5 cycloalkylene, a C5 cycloalkenylene, or a 5-membered heterocyclene containing a nitrogen ring atom, where A 1 is one or more R 4 optionally substituted with; Each R 4 are independently halogen, CN, OR 5 , oxo (=O) in which the ring is at least partially saturated, or C 1~6 alkyl, where C 1~6alkyl is optionally substituted with one or more halogens which may be the same or different; R 5 is H or C 1~6 alkyl, where C 1~6 alkyl is optionally substituted with one or more halogens which may be the same or different; A 2 is phenyl or a 5- to 6-membered aromatic heterocyclyl, preferably phenyl or a 6-membered aromatic heterocyclyl, where A 2 is one or more R 6 optionally substituted with; Each R 6 are independently OH, O(C 1~6 Alkyl), halogen, CN, cyclopropyl, C 1~6 Alkyl, C 2~6 Alkenyl or C 2~6 alkynyl, where cyclopropyl, C 1~6 Alkyl, C 2~6 Alkenyl and C 2~6 alkynyl is optionally substituted with one or more halogens which may be the same or different; or The Two R's 6 are connected together with the atoms to which they are attached to the ring A 2a Forming; A 2a is phenyl; C 3~7 cycloalkyl; or 3- to 7-membered heterocyclyl, where A 2a is one or more R 7 optionally substituted with; Each R 7 independently, C 1~6 Alkyl, C 2~6 Alkenyl or C 2~6 alkynyl, where C 1~6 Alkyl, C 2~6 Alkenyl and C 2~6 alkynyl is optionally substituted with one or more halogens which may be the same or different; R1 is H or C 1~4 alkyl, preferably H, where C 1~4 alkyl is optionally substituted with one or more halogens which may be the same or different; R 2 is H or C 1~4 alkyl, where C 1~4 alkyl is optionally substituted with one or more halogens which may be the same or different; R 3 is A 3 or R 2 and R 3 is connected to one or more R 8 forming a 3,4-dihydro-2H-1-benzopyran ring optionally substituted with A 3 is phenyl or a 5- to 6-membered aromatic heterocyclyl, preferably phenyl or a 6-membered aromatic heterocyclyl, wherein A 3 is one or more R 8 optionally substituted with; Each R 8 are independently halogen, CN, C(O)OR 9 , OR 9 , C(O)R 9 , C(O)N(R 9 R 9a ), S(O)2N(R 9 R 9a ), S(O)N(R 9 R 9a ), S(O)2R 9 , S(O)R 9 , N(R 9 )S(O)2N(R 9a R 9b ), SR 9 , N(R 9 R 9a ), NO2, OC(O)R 9 , N(R 9 )C(O)R 9a , N(R 9 )S(O)2R 9a , N(R9 )S(O)R 9a , N(R 9 )C(O)OR 9a , N(R 9 )C(O)N(R 9a R 9b ), OC(O)N(R 9 R 9a ), oxo (=O) where the ring is at least partially saturated, C 1~6 Alkyl, C 2~6 Alkenyl, or C 2~6 alkynyl, where C 1~6 Alkyl, C 2~6 Alkenyl and C 2~6 Alkynyl is a group consisting of one or more R 10 optionally substituted with; R 9 , R 9a , R 9b is H, C 1~6 Alkyl, C 2~6 Alkenyl and C 2~6 alkynyl, wherein C 1~6 Alkyl, C 2~6 Alkenyl and C 2~6 alkynyl is optionally substituted with one or more halogens which may be the same or different; Each R 10 are independently halogen, CN, C(O)OR 11 , OR 11 , C(O)R 11 , C(O)N(R 11 R 11a ), S(O)2N(R 11 R 11a ), S(O)N(R 11 R 11a ), S(O)2R 11 , S(O)R 11 , N(R 11 )S(O)2N(R 11a R 11b ), SR 11 , N(R 11 R 11a ), NO2, OC(O)R 11 , N(R 11 )C(O)R11a , N(R 11 )SO2R 11a , N(R 11 )S(O)R 11a , N(R 11 )C(O)N(R 11a R 11b ), N(R 11 )C(O)OR 11a , or OC(O)N(R 11 R 11a ) and; R 11 , R 11a , R 11b is H, C 1~6 Alkyl, C 2~6 Alkenyl and C 2~6 alkynyl, wherein C 1~6 Alkyl, C 2~6 Alkenyl and C 2~6 Alkynyl is optionally substituted with one or more halogens which may be the same or different.

[0016] A variable or substituent can be selected from a group of different variants, and when such a variable or substituent occurs more than once, each variant can be the same or different.

[0017] Within the meaning of the present invention, the terms are used as follows:

[0018] The term "optionally substituted" means unsubstituted or substituted. Generally, but without limitation, "one or more substituents" means 1, 2, or 3, preferably 1 or 2, and more preferably 1 substituent. Generally, these substituents can be the same or different.

[0019] "Alkyl" means a straight or branched hydrocarbon chain. Each hydrogen of an alkyl carbon can be replaced by a substituent as further specified.

[0020] "Alkenyl" means a straight or branched hydrocarbon chain containing at least one carbon-carbon double bond. Each hydrogen of an alkenyl carbon can be replaced by a substituent as further specified.

[0021] "Alkynyl" means a straight or branched hydrocarbon chain containing at least one carbon-carbon triple bond. Each hydrogen of an alkynyl carbon can be replaced by a substituent as further specified.

[0022] "C 1~4 "Alkyl" means, for example, an alkyl chain having 1 to 4 carbon atoms at the end of the molecule, if present: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, or, when two parts of the molecule are connected by an alkyl group, for example, -CH2-, -CH2-CH2-, -CH(CH3)-, -CH2-CH2-CH2-, -CH(C2H5)-, -C(CH3)2-. C 1~4 Each hydrogen of an alkyl carbon can be replaced by a substituent as further specified.

[0023] "C 1~6 "Alkyl" refers to, for example, an alkyl chain having 1 to 6 carbon atoms at the end of the molecule, if present: C 1~4 Alkyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl, or when two parts of the molecule are connected by an alkyl group, for example, -CH2-, -CH2-CH2-, -CH(CH3)-, -CH2-CH2-CH2-, -CH(C2H5)-, -C(CH3)2-. C 1~6 Each hydrogen of an alkyl carbon can be replaced by a substituent as further specified.

[0024] "C 2~6"Alkenyl" means, for example, an alkenyl chain having 2 to 6 carbon atoms, if present, at the end of the molecule: -CH=CH2, -CH=CH-CH3, -CH2-CH=CH2, -CH=CH-CH2-CH3, -CH=CH-CH=CH2, or, if two parts of the molecule are linked by an alkenyl group, for example, -CH=CH-. 2~6 Each hydrogen of an alkenyl carbon can be replaced by a substituent as further specified.

[0025] "C 2~6 "Alkynyl" means, for example, an alkynyl chain having 2 to 6 carbon atoms at the end of the molecule, if present: -C≡CH, -CH2-C≡CH, CH2-CH2-C≡CH, CH2-C≡C-CH3, or, if two parts of the molecule are linked by an alkynyl group, for example, -C≡C-. 2~6 Each hydrogen of an alkynyl carbon can be replaced by a substituent as further specified.

[0026] "C 3~7 cycloalkyl" or "C 3~7 "Cycloalkyl ring" means a cyclic alkyl chain having 3 to 7 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl. Preferably, cycloalkyl refers to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl. Each hydrogen of a cycloalkyl carbon can be replaced by a substituent as further specified herein. "C 3~5 cycloalkyl" or "C 3~5 The term "cycloalkyl ring" is defined accordingly.

[0027] "C5 cycloalkylene" refers to a divalent cycloalkyl having 5 carbon atoms, i.e., a divalent cyclopentyl ring.

[0028] "C5 cycloalkenylene" refers to a divalent cycloalkenylene, i.e., a divalent cyclopentene or cyclopentadiene.

[0029] "Halogen" means fluoro, chloro, bromo or iodo. It is generally preferred that halogen is fluoro or chloro.

[0030] A "3- to 7-membered heterocyclyl" or "3- to 7-membered heterocycle" means a ring having 3, 4, 5, 6, or 7 ring atoms, which may contain up to a maximum number of double bonds (aromatic or non-aromatic ring that is fully, partially, or unsaturated), wherein at least one ring atom and up to four ring atoms are replaced by a heteroatom selected from the group consisting of sulfur (including -S(O)-, -S(O)-), oxygen, and nitrogen (including =N(O)-), and the ring is connected to the remainder of the molecule through a carbon or nitrogen atom. Examples for 3- to 7-membered heterocycles are aziridine, azetidine, oxetane, thietane, furan, thiophene, pyrrole, pyrroline, imidazole, imidazoline, pyrazole, pyrazoline, oxazole, oxazoline, isoxazole, isoxazoline, thiazole, thiazoline, isothiazole, isothiazolidine, thiadiazole, thiadiazoline, tetrahydrofuran, tetrahydrothiophene, pyrrolidine, imidazolidine, pyrazolidine, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, thiadiazolidine, sulfolane, pyran, dihydropyran, tetrahydropyran, imidazolidine, pyridine, pyridazine, pyrazine, pyrimidine, piperazine, piperidine, morpholine, tetrazole, triazole, triazolidine, tetrazolidine, diazepane, azepine or homopiperazine. The term "5- to 6-membered heterocyclyl" or "5- to 6-membered heterocycle" is defined accordingly. The term "5-membered heterocyclyl" or "5-membered heterocycle" is defined accordingly and includes 5-membered aromatic heterocyclyls or heterocycles.

[0031] The term "nitrogen ring atom-containing five-membered heterocyclene" refers to a divalent five-membered heterocycle in which at least one of the five ring atoms is a nitrogen atom and the ring is connected to the remainder of the molecule through a carbon or nitrogen atom.

[0032] A "saturated 4- to 7-membered heterocyclyl" or "saturated 4- to 7-membered heterocycle" means a fully saturated "4- to 7-membered heterocyclyl" or "4- to 7-membered heterocycle".

[0033] A "4- to 7-membered at least partially saturated heterocyclyl" or "4- to 7-membered at least partially saturated heterocycle" means a "4- to 7-membered heterocyclyl" or "4- to 7-membered heterocycle" that is at least partially saturated.

[0034] "5- to 6-membered aromatic heterocyclyl" or "5- to 6-membered aromatic heterocycle" means a heterocycle derived from cyclopentadienyl or benzene, in which at least one carbon atom is replaced by a heteroatom selected from the group consisting of sulfur (including -S(O)-, -S(O)2-), oxygen, and nitrogen (including =N(O)-). Examples of such heterocycles are furan, thiophene, pyrrole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, thiadiazole, triazole, tetrazole, pyridine, pyrimidine, pyridazine, pyrazine, and triazine.

[0035] "5-membered aromatic heterocyclyl" or "5-membered aromatic heterocycle" means a heterocycle derived from cyclopentadienyl, in which at least one carbon atom is replaced by a heteroatom selected from the group consisting of sulfur (including -S(O)-, -S(O)-), oxygen, and nitrogen (including =N(O)-). Examples of such heterocycles are furan, thiophene, pyrrole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, thiadiazole, triazole, and tetrazole.

[0036] A "7- to 12-membered heterobicyclyl" or "7- to 12-membered heterobicycle" means a two-ring heterocyclic system having 7 to 12 ring atoms, wherein at least one ring atom is shared by both rings and the system can contain up to a maximum number of double bonds (aromatic or non-aromatic rings that are fully, partially, or unsaturated), and wherein at least one ring atom and up to six ring atoms are replaced by a heteroatom selected from the group consisting of sulfur (including -S(O)-, -S(O)-), oxygen, and nitrogen (including =N(O)-), and the ring is linked to the remainder of the molecule via a carbon or nitrogen atom. Examples for 7- to 12-membered heterobicycles are indole, indoline, benzofuran, benzothiophene, benzoxazole, benzisoxazole, benzothiazole, benzisothiazole, benzimidazole, benzimidazoline, quinoline, quinazoline, dihydroquinazoline, quinoline, dihydroquinoline, tetrahydroquinoline, decahydroquinoline, isoquinoline, decahydroisoquinoline, tetrahydroisoquinoline, dihydroisoquinoline, benzazepine, purine or pteridine. The term 7- to 12-membered heterobicycle also includes two-ring spiro structures such as 6-oxa-2-azaspiro[3,4]octane, 2-oxa-6-azaspiro[3.3]heptan-6-yl or 2,6-diazaspiro[3.3]heptan-6-yl, or bridged heterocycles such as 8-aza-bicyclo[3.2.1]octane or 2,5-diazabicyclo[2.2.2]octan-2-yl or 3,8-diazabicyclo[3.2.1]octane.

[0037] "Saturated 7- to 12-membered heterobicyclyl" or "saturated 7- to 12-membered heterobicycle" means a fully saturated 7- to 12-membered heterobicyclyl or 7- to 12-membered heterobicycle.

[0038] A "7- to 12-membered at least partially saturated heterobicyclyl" or "7- to 12-membered at least partially saturated heterobicycle" means a "7- to 12-membered heterobicyclyl" or "7- to 12-membered heterobicycle" that is at least partially saturated.

[0039] A "9- to 11-membered aromatic heterobicyclyl" or "9- to 11-membered aromatic heterobicycle" means a two-ring heterocyclic system, wherein at least one ring is aromatic, the heterocyclic ring system having 9 to 11 ring atoms, wherein two ring atoms are shared by both rings and the system can contain up to a maximum number of double bonds (fully or partially aromatic), wherein at least one ring atom and up to six ring atoms are replaced by a heteroatom selected from the group consisting of sulfur (including -S(O)-, -S(O)-), oxygen, and nitrogen (including =N(O)-), and wherein the ring is linked to the remainder of the molecule via a carbon or nitrogen atom. Examples of 9- to 11-membered aromatic heterobicycles are indole, indoline, benzofuran, benzothiophene, benzoxazole, benzisoxazole, benzothiazole, benzisothiazole, benzimidazole, benzimidazoline, quinoline, quinazoline, dihydroquinazoline, dihydroquinoline, tetrahydroquinoline, isoquinoline, tetrahydroisoquinoline, dihydroisoquinoline, benzazepine, purine or pteridine. The terms "9- to 10-membered aromatic heterobicyclyl" or "9- to 10-membered aromatic heterobicycle" are defined accordingly.

[0040] Preferred compounds of formula (I) are those in which one or more of the residues contained therein have the meanings given below, and all combinations of preferred substituent definitions are subject of the present invention. For all preferred compounds of formula (I), the present invention also includes all tautomeric and stereoisomeric forms and mixtures thereof in all ratios, as well as their pharmaceutically acceptable salts.

[0041] In preferred embodiments of the invention, the substituents described below independently have the following meanings: Therefore, one or more of these substituents can have the preferred or more preferred meanings given below.

[0042] Preferably, A 1 is a nitrogen ring atom-containing five-membered heterocyclene, where A 1 is one or more R 4 is optionally replaced by

[0043] More preferably, A 1 is a nitrogen ring atom-containing 5-membered heterocyclene selected from the group of divalent heterocycles consisting of oxadiazole, imidazole, imidazolidine, pyrazole and triazole, preferably oxadiazole; A 1 is one or more R 4 is optionally replaced by

[0044] Preferably, A 1 is unsubstituted or contains one or two R 4 and preferably A 1 is non-substituted.

[0045] Preferably, R 4 is an oxo in which the ring is at least partially saturated.

[0046] Preferably, A 1 teeth, [ka] and more preferably, A 1 teeth, [ka] is.

[0047] Preferably, A 2is phenyl, pyridyl, pyrazinyl, pyridazinyl, pyrazolyl or 1,2,4-oxadiazolyl, where A 2 is one or more R 6 is optionally replaced by

[0048] Preferably, A 2 is phenyl, pyridyl, pyrazinyl, or pyridazinyl, where A 2 is one or more R 6 is optionally replaced by

[0049] Preferably, A 2 is one or two R's that may be the same or different 6 is replaced by .

[0050] Preferably, each R 6 are independently F, Cl, CF3, OCH3, CH3, CH2CH3, or cyclopropyl.

[0051] Preferably, R 2 is H.

[0052] Preferably, R 3 is A 3 is.

[0053] Preferably, A 3 is phenyl, pyridyl, pyrazinyl or pyrimidazyl, where A 3 is one or more R 8 is optionally replaced by

[0054] Preferably, A 3 is one or two R's that may be the same or different 8 is replaced by .

[0055] Preferably, R 2 and R 3are connected to form a dihydrobenzopyran ring, wherein the ring is joined to one or more R 8 and preferably the ring is optionally substituted with one or two R 8 Thus, preferred formula (I) is the formula (Ia) [ka] is.

[0056] However, in another preferred embodiment, R 3 is A 3 is.

[0057] Preferably, R 8 are independently F, Cl, CF3, CH=O, CH2OH, or CH3.

[0058] Compounds of formula (I) in which some or all of the radicals mentioned above have the preferred or more preferred meanings are also a subject of the present invention.

[0059] Preferred specific compounds of the present invention are 2-(4-chloro-3-fluorophenoxy)-N-[(3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]oxan-3-yl]acetamide, 2-(4-chlorophenoxy)-N-[(3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]oxan-3-yl]acetamide, 2-(4-chloro-3-fluorophenoxy)-N-[(3R,6S)-6-{5-[6-(trifluoromethyl)pyridin-3-yl]-1,3,4-oxadiazol-2-yl}oxan-3-yl]acetamide, 2-(4-chloro-3-fluorophenoxy)-N-[(3S,6R)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]oxan-3-yl]acetamide, 2-(4-chloro-3-fluorophenoxy)-N-[(3R,6S)-6-[5-(6-cyclopropylpyridin-3-yl)-1,3,4-oxadiazol-2-yl]oxan-3-yl]acetamide, 2-(4-chloro-3-fluorophenoxy)-N-[(3R,6S)-6-[5-(6-ethylpyridin-3-yl)-1,3,4-oxadiazol-2-yl]oxan-3-yl]acetamide, 2-[(6-chloro-5-fluoropyridin-3-yl)oxy]-N-[(3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]oxan-3-yl]acetamide, N-[(3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]oxan-3-yl]-2-{[2-(trifluoromethyl)pyridin-4-yl]oxy}acetamide, N-[(3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]oxan-3-yl]-2-[(6-chloropyridin-3-yl)oxy]acetamide, N-[(3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]oxan-3-yl]-2-[(5-fluoro-6-methylpyridin-3-yl)oxy]acetamide, 2-[(6-chloro-5-fluoropyridin-3-yl)oxy]-N-[(3R,6S)-6-[5-(6-chloropyridin-3-yl)-1,3,4-oxadiazol-2-yl]oxan-3-yl]acetamide, N-[(3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]oxan-3-yl]-2-[(6-methylpyridin-3-yl)oxy]acetamide, N-[(3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]oxan-3-yl]-2-[(5-chloropyrazin-2-yl)oxy]acetamide, N-[(3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]oxan-3-yl]-2-[(2-chloropyrimidin-5-yl)oxy]acetamide, 2-[(5-chloro-6-methylpyridin-3-yl)oxy]-N-[(3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]oxan-3-yl]acetamide, 2-(4-chloro-3-fluorophenoxy)-N-[(3R,6S)-6-{5-[5-(trifluoromethyl)pyridin-3-yl]-1,3,4-oxadiazol-2-yl}oxan-3-yl]acetamide, 2-(4-chloro-3-fluorophenoxy)-N-[(3R,6S)-6-{5-[2-(trifluoromethyl)pyridin-4-yl]-1,3,4-oxadiazol-2-yl}oxan-3-yl]acetamide, N-[3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]tetrahydropyran-3-yl]-2-[[6-(trifluoromethyl)-3-pyridyl]oxy]acetamide, or N-[(3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]oxan-3-yl]-2-{[5-(trifluoromethyl)pyridin-3-yl]oxy}acetamide is selected from the group consisting of:

[0060] Where tautomerism, such as keto-enol tautomerism, of the compounds of formula (I) may occur, the individual forms, such as keto and enol forms, are included both separately and together as mixtures in any ratio. The same applies to stereoisomers, such as enantiomers, cis / trans isomers, conformers, etc.

[0061] In particular, when enantiomeric or diastereomeric forms are shown in a compound according to formula (I), each pure form separately and any mixture of at least two of the pure forms in any ratio are encompassed by formula (I) and are subject of the present invention.

[0062] A preferred formula (I) is the formula (Ib) [ka] is.

[0063] Isotopically labeled compounds of formula (I) are also within the scope of the present invention. Methods for isotopic labeling are known in the art. Preferred isotopes are those of the elements H, C, N, O and S. Solvates and hydrates of compounds of formula (I) are also within the scope of the present invention.

[0064] If desired, isomers can be separated by methods well known in the art, for example, by liquid chromatography. The same applies to enantiomers, for example, by using a chiral stationary phase. Additionally, enantiomers can be isolated by converting them into diastereomers, i.e., coupling with an enantiomerically pure auxiliary compound, subsequent separation of the resulting diastereomers, and cleavage of the auxiliary residue. Alternatively, any enantiomer of the compound of formula (I) can be obtained from stereoselective synthesis using optically pure starting materials, reagents, and / or catalysts.

[0065] When a compound according to formula (I) contains one or more acidic or basic groups, the present invention also includes their corresponding pharmaceutically or toxicologically acceptable salts, particularly their pharmaceutically usable salts. Thus, compounds of formula (I) containing acidic groups can be used according to the present invention, for example, as alkali metal salts, alkaline earth metal salts, or ammonium salts. More precise examples of such salts include sodium salts, potassium salts, calcium salts, magnesium salts, or salts with ammonia or organic amines, such as ethylamine, ethanolamine, triethanolamine, or amino acids. Compounds of formula (I) containing one or more basic groups, i.e., groups that can be protonated, can exist and be used according to the present invention in the form of their addition salts with inorganic or organic acids. Examples of suitable acids include hydrogen chloride, hydrogen bromide, phosphoric acid, sulfuric acid, nitric acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, oxalic acid, acetic acid, tartaric acid, lactic acid, salicylic acid, benzoic acid, formic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, malic acid, sulfamic acid, phenylpropionic acid, gluconic acid, ascorbic acid, isonicotinic acid, citric acid, adipic acid, and other acids known to those skilled in the art. If the compound of formula (I) contains both acidic and basic groups in the molecule, the present invention includes inner salts or betaines (zwitterions) in addition to the salt forms described. The respective salts according to formula (I) can be obtained by conventional methods known to those skilled in the art, such as by contacting them with organic or inorganic acids or bases in a solvent or dispersant, or by anion or cation exchange with other salts. The present invention also includes all salts of compounds of formula (I) which, because of their low physiological compatibility, are not directly suitable for use in medicines but which can be used, for example, as intermediates for chemical reactions or for the preparation of pharmaceutically acceptable salts.

[0066] As demonstrated below, the compounds of the present invention are believed to be suitable for modulating the integrated stress response pathway.

[0067] The integrated stress response (ISR) is a cellular stress response common to all eukaryotes. (1) Dysregulation of ISR signaling has important pathological consequences, leading to inflammation, viral infections, diabetes, cancer, and neurodegenerative diseases, among others.

[0068] ISR is a common factor in different types of cellular stress that results in phosphorylation of the alpha subunit of eukaryotic translation initiation factor 2 (eIF2alpha) on serine 51, leading to the repression of normal protein synthesis and the expression of stress-response genes (2). In mammalian cells, this phosphorylation is carried out by a family of four eIF2alpha kinases, each of which responds to distinct environmental and physiological stresses: PKR-like ER kinase (PERK), double-stranded RNA-dependent protein kinase (PKR), heme-regulated eIF2alpha kinase (HRI), and general control non-derepressible 2 (GCN2) (3).

[0069] eIF2 alpha, together with eIF2 beta and eIF2 gamma, forms the eIF2 complex, a key player in the initiation of normal mRNA translation (4). The eIF2 complex mediates the initiation of mRNA translation by catalyzing GTP and Met-tRNA. i to form the ternary complex (eIF2-GTP-Met-tRNA) that is recruited by the ribosome for translation initiation. i ) to form (5, 6).

[0070] eIF2B is a heterodecameric complex consisting of five subunits (alpha, beta, gamma, delta, and epsilon) that, in duplicate, form a GEF-active decamer ( 7 ).

[0071] In response to ISR activation, phosphorylated eIF2alpha inhibits eIF2B-mediated exchange of GDP for GTP, resulting in reduced ternary complex formation and, therefore, inhibition of translation of normal mRNAs characterized by ribosome binding to the 5'AUG start codon (8). Under these conditions of reduced ternary complex abundance, translation of several specific mRNAs, including the mRNA encoding the transcription factor ATF4, is activated through a mechanism involving altered translation of upstream ORFs (uORFs) (7, 9, 10). Under these conditions of reduced ternary complex abundance, translation of several specific mRNAs, including the mRNA encoding the transcription factor ATF4, is activated through a mechanism involving altered translation of upstream ORFs (uORFs) (7, 9, 10). These mRNAs typically contain one or more uORFs that function normally in unstressed cells to restrict ribosome flow to the primary coding ORF. For example, under normal conditions, the uORF in the 5'UTR of ATF occupies ribosomes and prevents translation of the ATF4 coding sequence. However, under stress conditions, i.e., under conditions of reduced ternary complex formation, the probability that ribosomes will scan past these upstream ORFs and begin translation at the ATF4-encoding ORF is increased. ATF4 and other stress response factors expressed in this manner subsequently direct the expression of an array of additional stress response genes. The acute phase consists in the expression of proteins aimed at restoring homeostasis, while the chronic phase leads to the expression of pro-apoptotic factors (1, 11, 12, 13).

[0072] Upregulation of markers of ISR signaling has been demonstrated in a variety of conditions, including cancer and neurodegenerative diseases. In cancer, ER stress-regulated translation increases resistance to hypoxic conditions and promotes tumor growth (14, 15, 16), and genetic deletion of PERK results in the transformation of PERK. - / -It has been shown to slow the growth of tumors derived from mouse embryonic fibroblasts (14, 17). Furthermore, a recent report provided proof of concept that activators of eIF2B are effective in treating aggressive metastatic forms of prostate cancer using patient-derived xenograft modeling in mice (28). Taken together, prevention of cytoprotective ISR signaling may represent an effective antiproliferative strategy for the treatment of at least some forms of cancer.

[0073] Furthermore, modulation of ISR signaling has proven effective in preserving synaptic function and reducing neuronal loss, as well as in neurodegenerative diseases characterized by activation of the misfolded and unfolded protein response (UPR), such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease (AD), Parkinson's disease (PD), and Jakob-Creutzfeldt disease (prion disease) (18, 19, 20). There are examples of neurodegenerative diseases, such as prion disease, where pharmacological as well as genetic inhibition of ISR signaling has been shown to normalize protein translation levels, rescue synaptic function, and prevent neuronal loss (21). Specifically, reducing the level of phosphorylated eIF2α by overexpressing a phosphatase that controls phosphorylated eIF2α increased the survival time of prion-infected mice, whereas sustained eIF2α phosphorylation decreased survival (22).

[0074] Furthermore, direct evidence for the importance of controlling protein expression levels for proper brain function exists in the form of rare genetic diseases affecting the function of eIF2 and eIF2B. Mutations in eIF2gamma, which disrupt the integrity of the eIF2 complex and therefore result in a reduction of normal protein expression levels, lead to intellectual disability syndrome (ID) (23). Partial loss of function mutations in the eIF2B subunit have been shown to be responsible for the rare leukodystrophy vanishing white matter disease (VWMD) (24, 25). Specifically, stabilization of partial loss of function eIF2B in a VWMD mouse model with a small molecule related to ISRIB has been shown to reduce ISR markers and improve functional as well as pathological endpoints (26, 27).

[0075] The present invention provides compounds of the invention, in free form or in pharmaceutically acceptable salt form, for use in the treatment of the diseases or disorders described herein.

[0076] Thus, a further aspect of the invention is a compound of the invention, or a pharmaceutically acceptable salt thereof, for use as a pharmaceutical.

[0077] The described methods of treatment can be applied to mammals such as dogs, cats, cows, horses, rabbits, monkeys and humans. Preferably, the mammalian patient is a human patient.

[0078] Thus, the present invention provides a compound of the present invention, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of one or more diseases or disorders associated with the integrated stress response.

[0079] A further aspect of the present invention is a compound of the present invention, or a pharmaceutically acceptable salt thereof, for use in a method for treating or preventing one or more disorders or diseases associated with the integrated stress response.

[0080] A further aspect of the present invention is the use of a compound of the present invention, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of one or more disorders or diseases associated with the integrated stress response.

[0081] Yet another aspect of the present invention is a method for treating, controlling, delaying or preventing one or more diseases or disorders associated with the integrated stress response in a mammalian patient in need of such treatment, which method comprises administering to said patient a therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof.

[0082] The present invention provides a compound of the invention, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of one or more of the diseases or disorders described below.

[0083] A further aspect of the present invention is a compound of the present invention, or a pharmaceutically acceptable salt thereof, for use in a method of treating or preventing one or more of the disorders or diseases described below.

[0084] A further aspect of the invention is the use of a compound of the invention, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of one or more of the disorders or diseases described below.

[0085] Yet another aspect of the present invention is a method for treating, controlling, delaying or preventing one or more of the diseases or disorders described below in a mammalian patient in need of such treatment, which method comprises administering to said patient a therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof.

[0086] The disease or disorder includes, but is not limited to, a disease selected from the group consisting of leukodystrophies, intellectual disability syndromes, neurodegenerative diseases and disorders, neoplastic diseases, infectious diseases, inflammatory diseases, musculoskeletal diseases, metabolic diseases, ocular diseases, as well as organ fibrosis, chronic and acute diseases of the liver, chronic and acute diseases of the lung, chronic and acute diseases of the kidney, myocardial infarction, cardiovascular diseases, arrhythmias, atherosclerosis, spinal cord injury, ischemic stroke, and neuropathic pain.

[0087] Leukodystrophy Examples of leukodystrophies include, but are not limited to, vanishing white matter disease with CNS hypomyelination (VWMD) and childhood ataxia (e.g., associated with defects in the function of eIF2 or components in signal transduction or signaling pathways including eIF2).

[0088] Intellectual disability syndrome Intellectual disability specifically refers to a condition in which a person has certain limitations in intellectual functions, such as communicating and caring for themselves, and / or has a deficit in social skills. Intellectual disability syndromes include, but are not limited to, intellectual disability conditions associated with a deficiency in the function of eIF2 or components in signal transduction or signal transduction pathways, including eIF2.

[0089] Neurodegenerative diseases / disorders Examples of neurodegenerative diseases and disorders include, but are not limited to, Alexander disease, Alper's disease, Alzheimer's disease, amyotrophic lateral sclerosis, ataxia-telangiectasia, Batten disease (also known as Spielmeyer-Voigt-Sjogren-Batten disease), bovine spongiform encephalopathy (BSE), Canavan disease, Cockayne syndrome, corticobasal degeneration, Creutzfeldt-Jakob disease, frontotemporal dementia, Gerstmann-Straussler-Scheiker syndrome, Huntington's disease, HIV-associated dementia, Kennedy disease, Krabbe disease, Coutts-Barr syndrome, and HIV-associated dementia. These include Lewy body dementia, Lewy body dementia, Machado-Joseph disease (spinocerebellar degeneration type 3), multiple sclerosis, multiple system atrophy, narcolepsy, neuroborreliosis, Parkinson's disease, Pelizaeus-Merzbacher disease, Pick's disease, primary lateral sclerosis, prion diseases, progressive supranuclear palsy, Refsum disease, Sandhoff disease, Schilder's disease, subacute combined degeneration of the spinal cord secondary to pernicious anemia, schizophrenia, spinocerebellar degeneration (multiple types with variable features), spinal muscular atrophy, Steele-Richardson-Olszewski disease, spinal cord deafness, and tauopathies.

[0090] In particular, the neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.

[0091] Neoplastic disease Neoplastic disease, in the broadest sense, can be understood as any tissue resulting from misregulation of cell growth. In many cases, neoplasms lead to at least a bulky tissue mass, possibly innervated by blood vessels. It may or may not involve the formation of one or more metastases / metastases. The neoplastic disease of the present invention can be any neoplasm as classified by the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) classification C00-D48.

[0092] By way of example, a neoplastic disease according to the present invention may be the presence of one or more malignant neoplasm(s) (tumors) (ICD-10 classifications C00-C97), may be the presence of one or more in situ neoplasm(s) (ICD-10 classifications D00-D09), may be the presence of one or more benign neoplasm(s) (ICD-10 classifications D10-D36), or may be the presence of one or more neoplasm(s) of indeterminate or unknown behavior (ICD-10 classifications D37-D48). Preferably, a neoplastic disease according to the present invention refers to the presence of one or more malignant neoplasm(s), i.e., malignant neoplasms (ICD-10 classifications C00-C97).

[0093] In a more preferred embodiment, the neoplastic disease is cancer.

[0094] Cancer can be understood in the broadest sense as any malignant neoplastic disease, i.e., the presence of one or more malignant neoplasms in a patient. Cancer can be a solid or hematological malignancy. Contemplated herein are, but are not limited to, leukemia, lymphoma, carcinoma, and sarcoma.

[0095] In particular, neoplastic diseases such as cancers characterized by upregulated ISR markers are included herein.

[0096] Illustrative cancers include, but are not limited to, thyroid cancer, cancers of the endocrine system, pancreatic cancer, brain cancer (e.g., glioblastoma multiforme, glioma), breast cancer (e.g., ER-positive, ER-negative, chemotherapy-resistant, herceptin-resistant, HER2-positive, doxorubicin-resistant, tamoxifen-resistant, ductal carcinoma, lobular carcinoma, primary, metastatic), cervical cancer, ovarian cancer, uterine cancer, colon cancer, head and neck cancer, liver cancer (e.g., hepatocellular carcinoma), kidney cancer, lung cancer (e.g., non-small cell lung carcinoma, squamous cell lung carcinoma, adenocarcinoma, large cell lung carcinoma, small cell lung carcinoma, carcinoid, sarcoma), colon cancer, esophageal cancer, stomach cancer, bladder cancer, bone cancer, stomach cancer, prostate cancer, and skin cancer (e.g., melanoma).

[0097] Further examples include, but are not limited to, myeloma, leukemia, mesothelioma, and sarcoma.

[0098] Additional examples include, but are not limited to, medulloblastoma, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, neuroblastoma, glioma, glioblastoma multiforme, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, primary brain tumors, malignant pancreatic insulinoma, malignant carcinoid, urinary bladder cancer, premalignant skin lesions, testicular cancer, lymphoma, genitourinary cancer, malignant hypercalcemia, endometrial cancer, adrenocortical carcinoma, neoplasms of the endocrine or exocrine pancreas, medullary thyroid cancer, medullary thyroid carcinoma, melanoma, colorectal cancer, papillary thyroid cancer, hepatocellular carcinoma, Paget's disease of the nipple, phyllodes tumor, lobular carcinoma, ductal carcinoma, carcinoma of the pancreatic stellate cells, and carcinoma of the hepatic stellate cells.

[0099] Illustrative leukemias include, but are not limited to, acute nonlymphocytic leukemia, chronic lymphocytic leukemia, acute granulocytic leukemia, chronic granulocytic leukemia, acute promyelocytic leukemia, adult T-cell leukemia, aleukemic leukemia, non-leukocythemic leukemia, basophilic leukemia, blast cell leukemia, bovine leukemia, chronic myelocytic leukemia, leukemia cutis, embryonic leukemia, eosinophilic leukemia, Gross' leukemia, hairy cell leukemia, hemoblastic leukemia, hemoblastic leukemia, histiocytic leukemia, stem cell leukemia, acute monocytic leukemia, acute myeloid ... Leukemia, leukopenic leukemia, lymphocytic leukemia, lymphoblastic leukemia, lymphocytic leukemia, lymphotropic leukemia, lymphocytic leukemia, lymphosarcoma cell leukemia, mast cell leukemia, megakaryocytic leukemia, micromyeloblastic leukemia, monocytic leukemia, myeloblastic leukemia, myelocytic leukemia, myelogranulocytic leukemia, myelomonocytic leukemia, Naegeli leukemia, plasma cell leukemia, multiple myeloma, plasma cell leukemia, promyelocytic leukemia, Leder cell leukemia, Schilling leukemia, stem cell leukemia, subleukemic leukemia, and anaplastic cell leukemia.

[0100] Illustrative sarcomas include, but are not limited to, chondrosarcoma, fibrosarcoma, lymphosarcoma, melanosarcoma, myxosarcoma, osteosarcoma, Abemethy's sarcoma, liposarcoma, liposarcoma, alveolar soft part sarcoma, ameloblastic sarcoma, botryoid sarcoma, chloroma sarcoma, choriocarcinoma, embryonal sarcoma, Wilms' tumor sarcoma, endometrial sarcoma, stromal sarcoma, Ewing's sarcoma, fascial sarcoma, fibroblastic sarcoma, giant cell sarcoma, and fibrosarcoma. These include cell sarcoma, granulocytic sarcoma, Hodgkin's sarcoma, idiopathic multiple pigmented hemorrhagic sarcoma, immunoblastic sarcoma of B cells, lymphoma, immunoblastic sarcoma of T cells, Jensen's sarcoma, Kaposi's sarcoma, Kupffer cell sarcoma, angiosarcoma, leukemia sarcoma, malignant mesenchymal sarcoma, parosteal sarcoma, reticulocytic sarcoma, Rous sarcoma, serous cystic sarcoma, synovial sarcoma, and telangiectatic sarcoma.

[0101] Illustrative melanomas include, but are not limited to, acral lentiginous melanoma, amelanotic melanoma, benign juvenile melanoma, Cloudman melanoma, S91 melanoma, Harding-Passey melanoma, juvenile melanoma, lentigo maligna melanoma, malignant melanoma, nodular melanoma, subungual melanoma, and superficial spreading melanoma.

[0102] Exemplary carcinomas include, but are not limited to, medullary thyroid carcinoma, familial medullary thyroid carcinoma, acinar carcinoma, adenoid cystic carcinoma, adenomatous carcinoma, carcinoma of the adrenal cortex, alveolar carcinoma, alveolar cell carcinoma, basal cell carcinoma, basaloid carcinoma, basal squamous cell carcinoma, bronchoalveolar carcinoma, bronchiolar carcinoma, bronchogenic carcinoma, cerebriform carcinoma, cholangiocellular carcinoma, choriocarcinoma, colloid carcinoma, comedo carcinoma, corpus carcinoma, cribriform carcinoma, armor carcinoma, skin carcinoma, cylindrical carcinoma, cylindrical cell carcinoma, ductal carcinoma, ductal carcinoma, compact carcinoma durum, embryonal carcinoma, encephalomyocarcinoma, epidermoid carcinoma, epithelial adenoid carcinoma, exophytic carcinoma, preulcerative carcinoma (carcinoma ex ulcere), fibrous carcinoma, gelatinous carcinoma, gelatinous carcinoma, giant cell carcinoma, adenocarcinoma, granulosa cell carcinoma, hair matrix carcinoma, hematoid carcinoma, hepatocellular carcinoma, Hurthle cell carcinoma, hyaline carcinoma, renal cell carcinoma, infantile embryonal carcinoma, carcinoma in situ, carcinoma in epidermis, carcinoma in situ carcinoma), Krompecher carcinoma, Kulchitzky cell carcinoma, large cell carcinoma, lenticular carcinoma, lipomatous carcinoma, lobular carcinoma, lymphoepithelial carcinoma, medullary carcinoma, melanotic carcinoma, soft carcinoma, mucinous carcinoma, mucinous adenocarcinoma (carcinoma muciparum), mucocellular carcinoma (carcinoma mucocellulare), mucoepidermoid carcinoma, mucinous carcinoma, mucinous carcinoma, myxomatous carcinoma (carcinoma myxomatodes), nasopharyngeal carcinoma, oat cell carcinoma, ossifying carcinoma, osteoid carcinoma, papillary carcinoma, periportal carcinoma, preinvasive carcinoma, squamous cell carcinoma, pasty carcinoma, renal cell carcinoma of the kidney, reserve cell carcinoma, sarcomatoid carcinoma, Schneiderian carcinoma, scirrhous carcinoma, scrotal carcinoma, signet ring cell carcinoma, simplex carcinoma, small cell carcinoma, solenoid carcinoma, spheroid cell carcinoma, spindle cell carcinoma, cavernous carcinoma, squamous cell carcinoma, linear carcinoma, angioectatic carcinoma, telangiectatic carcinoma, transitional cell carcinoma, nodular carcinoma, tubular carcinoma, nodular carcinoma, verrucous carcinoma, and choriocarcinoma.

[0103] infectious disease Examples include, but are not limited to, infections caused by viruses (such as infections caused by HIV-1: human immunodeficiency virus type 1; IAV: influenza A virus; HCV: hepatitis C virus; DENV: dengue virus; ASFV: African swine fever virus; EBV: Epstein-Barr virus; HSV1: herpes simplex virus 1; CHIKV: chikungunya virus; HCMV: human cytomegalovirus; SARS-CoV: severe acute respiratory syndrome coronavirus; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2), and infections caused by bacteria (such as infections caused by Legionella, Brucella, Simkania, Chlamydia, Helicobacter, and Campylobacter).

[0104] inflammatory diseases Examples of inflammatory diseases include, but are not limited to, postoperative cognitive dysfunction (decline in cognitive function after surgery), traumatic brain injury, arthritis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, multiple sclerosis, systemic lupus erythematosus (SLE), myasthenia gravis, juvenile-onset diabetes, type 1 diabetes mellitus, Guillain-Barré syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, ankylosing spondylitis, psoriasis, Sjogren's syndrome, vasculitis, glomerular vasculitis, and the like. Nephritis, autoimmune thyroiditis, Behcet's disease, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, ichthyosis, Graves' ophthalmopathy, inflammatory bowel disease, Addison's disease, vitiligo, asthma, allergic asthma, acne vulgaris, celiac disease, chronic prostatitis, inflammatory bowel disease, pelvic inflammatory disease, reperfusion injury, sarcoidosis, transplant rejection, interstitial cystitis, atherosclerosis, and atopic dermatitis.

[0105] musculoskeletal disorders Examples of musculoskeletal disorders include, but are not limited to, muscular dystrophy, multiple sclerosis, Friedrich's ataxia, muscle wasting disorders (e.g., muscle atrophy, sarcopenia, cachexia), inclusion body myopathy, progressive muscular atrophy, motor neuron disease, carpal tunnel syndrome, epicondylitis, tendonitis, back pain, muscle pain, muscle soreness, repetitive strain disorders, and paralysis.

[0106] metabolic disease Examples of metabolic diseases include, but are not limited to, diabetes (especially type II diabetes), non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), Niemann-Pick disease, liver fibrosis, obesity, heart disease, atherosclerosis, arthritis, cystinosis, phenylketonuria, proliferative retinopathy, and Kearns-Sayre disease.

[0107] eye disease Examples of ocular diseases include, but are not limited to, edema or neovascularization associated with any occlusive or inflammatory retinal vascular disorder, e.g., iris neovascularization, neovascular glaucoma, pterygium, neovascularization of the glaucoma filtering bleb, conjunctival papilloma; choroidal neovascularization, e.g., neovascular age-related macular degeneration (AMD), myopia, pre-uveitis, trauma, or idiopathic; macular edema, e.g., post-surgical macular edema, secondary to uveitis, including retinal and / or choroidal inflammation. macular edema due to diabetes, macular edema secondary to diabetes, and macular edema secondary to retinal vascular occlusive disease (i.e., branch retinal and central retinal vein occlusion); retinal neovascularization due to diabetes, e.g., retinal vein occlusion, uveitis, ocular ischemic syndrome from carotid artery disease, ocular or retinal artery occlusion, sickle cell retinopathy, other ischemic or occlusive neovascular retinopathies, retinopathy of prematurity, or Eales' disease; and genetic disorders, e.g., von Hippel-Lindau syndrome.

[0108] Further diseases Additional diseases include, but are not limited to, organ fibrosis (such as liver fibrosis, pulmonary fibrosis, or kidney fibrosis), chronic and acute diseases of the liver (such as fatty liver disease, or hepatic steatosis), chronic and acute diseases of the lungs, chronic and acute diseases of the kidneys, myocardial infarction, cardiovascular disease, arrhythmias, atherosclerosis, spinal cord injury, ischemic stroke, and neuropathic pain.

[0109] Yet another aspect of the present invention is a pharmaceutical composition comprising at least one compound of the present invention, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier, optionally in combination with one or more other biologically active compounds or pharmaceutical compositions.

[0110] Preferably, the one or more biologically active compounds are modulators of the integrated stress response pathway other than the compounds of formula (I).

[0111] "Pharmaceutical composition" refers to one or more active ingredients and one or more inactive ingredients that comprise the carrier, as well as any product that results directly or indirectly from the combination, complexation, or aggregation of any two or more of the ingredients, or from the dissociation of one or more of the ingredients, or from other types of reaction or interaction of one or more of the ingredients. Thus, the pharmaceutical composition of the present invention encompasses any composition made by admixing a compound of the present invention and a pharmaceutically acceptable carrier.

[0112] The pharmaceutical compositions of the present invention may contain one or more additional compounds as active ingredients, such as a mixture of compounds of formula (I) in the composition or other modulators of the integrated stress response pathway.

[0113] The active ingredients may be contained in one or more different pharmaceutical compositions (combination pharmaceutical compositions).

[0114] The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic bases or acids and organic bases or acids.

[0115] Compositions include those suitable for oral, rectal, topical, parenteral (including subcutaneous, intramuscular, and intravenous), ocular (ophthalmic), pulmonary (nasal or buccal inhalation) or intranasal administration, although the most suitable route in any given case will depend on the nature and severity of the condition being treated and on the nature of the active ingredient. They are conveniently presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy.

[0116] In practical use, the compound of formula (I) can be combined as an active ingredient in intimate admixture with pharmaceutical carriers according to conventional pharmaceutical compounding techniques.Carriers can take a variety of forms, depending on the desired form of preparation for administration, for example, oral or parenteral (including intravenous).When preparing compositions for oral dosage forms, any of the usual pharmaceutical media, such as water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, etc., can be used in the case of oral liquid preparations, such as suspensions, elixirs and solutions; or carriers, such as starch, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrants, etc., can be used in the case of oral solid preparations, such as powders, hard and soft capsules and tablets, and solid oral preparations are preferred over liquid preparations.

[0117] Due to their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form, and in this case, solid pharmaceutical carriers are obviously used.If desired, tablets can be coated by standard aqueous or non-aqueous techniques.Such compositions and preparations should contain at least 0.1% of active compound.The percentage of active compound in these compositions can of course vary, and can conveniently be between about 2% and about 60% by weight of the unit.The amount of active compound in such therapeutically useful compositions is such that an effective dosage is obtained.The active compound can also be administered intranasally, for example, as liquid drops or spray.

[0118] Tablets, pills, capsules, etc. may also contain binders such as tragacanth gum, acacia, corn starch, or gelatin; excipients such as dibasic calcium phosphate; disintegrants such as corn starch, potato starch, alginic acid; lubricants such as magnesium stearate; and sweeteners such as sucrose, lactose, or saccharin. When the dosage unit form is a capsule, it can contain, in addition to materials of the above type, a liquid carrier such as a fatty oil.

[0119] Various other materials may be present as coatings or to modify the physical form of the dosage unit. For example, tablets may be coated with shellac, sugar, or both. A syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, and a dye and flavoring, such as cherry or orange flavor.

[0120] The compound of formula (I) can also be administered parenterally. A solution or suspension of these active compounds can be prepared in water suitably mixed with a surfactant such as hydroxypropyl-cellulose. Dispersions can also be prepared in glycerin, liquid polyethylene glycol, and mixtures thereof in oils. Under normal conditions of storage and use, these preparations contain a preservative to prevent the growth of microbial organisms.

[0121] Pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.In all cases, the form should be sterile and fluid to the extent that easy syringeability exists.It should be stable under the conditions of manufacture and storage, and should be protected against the contaminating action of microorganisms such as bacteria and fungi.The carrier can be, for example, a solvent or dispersion medium containing water, ethanol, polyol (for example, glycerin, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.

[0122] Any suitable route of administration can be used to provide a mammal, especially a human, with an effective dose of the compound of the present invention. For example, oral, rectal, topical, parenteral, ocular, pulmonary, nasal, etc. Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments, aerosols, etc. Preferably, the compound of formula (I) is administered orally.

[0123] The effective dosage of the active ingredient employed can vary depending on the particular compound employed, the mode of administration, the condition being treated, and the severity of the condition being treated. Such dosages can be readily ascertained by one skilled in the art.

[0124] Starting materials for the synthesis of preferred embodiments of the present invention can be purchased from commercially available sources such as Array, Sigma Aldrich, Acros, Fisher, Fluka, ABCR, etc., or can be synthesized using known methods by those skilled in the art.

[0125] In general, several methods are applicable to preparing the compounds of the present invention. In some cases, various strategies are combined. Sequential or convergent routes are used. Illustrative synthetic routes are described below. [Example]

[0126] I Chemical Synthesis Testing Procedure: The following abbreviations and acronyms are used: aq water-based Brine A saturated solution of NaCl in water CV column volume δ Chemical shift in parts per million d doublet DCM dichloromethane dd Doublet of Doublets ddd doublet doublet doublet DMSO dimethyl sulfoxide DMSO-d6 Deuterated Dimethyl Sulfoxide DIPEA Diisopropylethylamine DMF Dimethylformamide ESI + Positive ionization mode ESI - Negative ionization mode EtOAc ethyl acetate Et2O diethyl ether HCl Hydrochloric acid HPLC High Performance Liquid Chromatography h hour(s) J NMR coupling constants MgSO4 Magnesium Sulfate m multiplet mL milliliter(s) min N2 nitrogen atmosphere Na2SO4 Sodium Sulfate NaHCO3 Sodium Bicarbonate NaOH Sodium hydroxide NMR nuclear magnetic resonance q Quintuplet rt room temperature RT retention time s singlet t triplet TBME tert-butyl methyl ether THF tetrahydrofuran HATU 1-[bis(dimethylamino)methylidene]-1H-[1,2,3]triazolo[4,5-b]pyridin-1-ium-3-oxide hexafluorophosphate

[0127] The analytical LCMS conditions are as follows:

[0128] System 1 (S1): Acidic IPC Method (MS17): Analytical METCR1410 HPLC-MS was performed on a Shimadzu LCMS-2010EV system using a reversed-phase Kinetex Core-Shell C18 column (2.1 mm x 50 mm, 5 μm; temperature: 40 °C) and a gradient of 5 to 100% B over 1.2 min (A = 0.1% formic acid in water; B = 0.1% formic acid in acetonitrile) followed by 100% B for 0.1 min at a flow rate of 1.2 mL / min with an injection volume of 3 μL. UV spectra were recorded at 215 nm using an SPD-M20A photodiode array detector. Mass spectra were acquired using an LCMS2010EV at a sampling rate of 2 scans per second over the m / z range of 150 to 850. Data were integrated and reported using Shimadzu LCMS-Solutions and PsiPort software.

[0129] System 2 (S2): Acidic Final Method (MSQ1 and MSQ2): Analytical MET-uHPLC-AB-101 HPLC-MS was performed on a Waters Acquity uPLC system with a Waters PDA and ELS detector, a Phenomenex Kinetex-XB C18 column (2.1 mm x 100 mm, 1.7 μM; temperature: 40 °C), and a gradient of 5 to 100% B over 5.3 min (A = 0.1% formic acid in water; B = 0.1% formic acid in acetonitrile) followed by 100% B for 0.5 min, at a flow rate of 0.6 mL / min with a 3 μL injection volume. UV spectra were recorded at 215 nm using a Waters Acquity photodiode array detector. Mass spectra were acquired using a Waters SQD at a sampling rate of 5 scans per second over the m / z range of 150 to 850. Data were integrated and reported using Waters MassLynx and OpenLynx software.

[0130] Analytical MET-uHPLC-AB-102 HPLC-MS was performed on a Waters Acquity uPLC system with a Waters PDA and ELS detector, using a Waters uPLC CSH C18 column (2.1 mm x 100 mm, 1.7 μM; temperature: 40 °C) and a gradient of 5 to 100% (A = 2 mM ammonium bicarbonate, buffered to pH 10 with ammonium hydroxide solution; B = acetonitrile) over 5.3 min, followed by 100% B for 0.5 min, at a flow rate of 0.6 mL / min. UV spectra were recorded at 215 nm using a Waters Acquity photodiode array detector. Mass spectra were acquired using a Waters Quatro Premier XE at a sampling rate of 5 scans per second over the m / z range of 150 to 850. Data were integrated and reported using Waters MassLynx and OpenLynx software.

[0131] System 3 (S3): Acidic Final Method (Shimadzu): 5% solvent B for 1 min, followed by a linear gradient from 5 to 100% solvent B in 5.5 min + 100% solvent B in 2.5 min, at a flow rate of 1.0 ml / min. Column: ATLANTIS dC18 (50 x 3.0 mm). Solvent A = 0.1% formic acid in water, solvent B = 0.1% formic acid in acetonitrile.

[0132] System 4 (S4): Basic final method (MS16) Analytical METCR1603 HPLC-MS was performed on an Agilent G1312A system with a Waters 2996 PDA detector and a Waters 2420 ELS detector using a Phenomenex Gemini-NX C18 column (2.0 × 100 mm, 3 mm column; temperature: 40 °C) and a gradient of 5 to 100% (A = 2 mM ammonium bicarbonate, buffered to pH 10; B = acetonitrile) over 5.5 min, followed by 100% B in 0.4 min, with an injection volume of 3 μL and a flow rate of 0.6 mL / min. UV spectra were recorded at 215 nm using a Waters Acquity photodiode array detector. Mass spectra were acquired using a Waters ZQ mass detector at a sampling rate of 5 scans per second over the m / z range of 150 to 850. Data were integrated and reported using Waters MassLynx and OpenLynx software.

[0133] The preparative HPLC conditions are as follows:

[0134] Method 1: Reversed-phase chromatography using acidic pH, standard elution method Purification by FCC on reversed-phase silica (acidic pH, standard elution method) was performed on a Biotage Isolera system using an appropriate SNAP C18 cartridge and a gradient of 10% B over 1.7 CV (A = 0.1% formic acid in water; B = 0.1% formic acid in acetonitrile) followed by 10 to 100% B over 19.5 CV and 100% B for 2 CV.

[0135] Scheme for Route 1: [ka]

[0136] Intermediate 1: [(3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]tetrahydropyran-3-yl]ammonium chloride [ka] To a solution of tert-butyl N-[(3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]tetrahydropyran-3-yl]carbamate (90%, 227 mg, 0.539 mmol) in DCM (1.35 mL) was added a solution of 4 M HCl in dioxane (1.4 mL, 5.40 mmol) at room temperature, and the reaction was stirred at this temperature for 1 h. The solvent was removed under reduced pressure to give [(3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]tetrahydropyran-3-yl]ammonium chloride (199 mg, 0.522 mmol, 97% yield) as an off-white powder. 1 H NMR (500 MHz, DMSO-d6) δ 8.17 (s, 3H), 8.08 - 7.96 (m, 2H), 7.75 - 7.64 (m, 2H), 4.90 (dd, J = 10.2, 2.5 Hz, 1H), 4.09 (dd, J = 10.8, M / Z: 280, 282 [M+H], ESI+, RT = 2.46 min (S4).

[0137] Step 1.1: tert-Butyl N-[(3R,6S)-6-[[(4-chlorobenzoyl)amino]carbamoyl]tetrahydropyran-3-yl]carbamate [ka] HATU (651 mg, 1.71 mmol) was added to a solution of 4-chlorobenzohydrazide (243 mg, 1.43 mmol) and DIPEA (0.75 mL, 4.28 mmol) in dry DMF (4 mL) at room temperature and stirred for 10 minutes. (2S,5R)-5-(tert-butoxycarbonylamino)tetrahydropyran-2-carboxylic acid (350 mg, 1.43 mmol) was then added, and the reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was diluted with water (30 mL) and EtO (30 mL), causing a brown solid to precipitate. The solid was filtered, washed with EtO, and the residual solvent was removed in vacuo to give tert-butyl N-[(3R,6S)-6-[[(4-chlorobenzoyl)amino]carbamoyl]tetrahydropyran-3-yl]carbamate (522 mg, 1.25 mmol, 87% yield) as a brown solid. 1 H NMR (400 MHz, DMSO-d6) δ 10.38 (s, 1H), 9.76 (s, 1H), 7.88 (d, J = 8.6 Hz, 2H), 7.57 (d, J = 8.6 Hz, 2H), 6.84 (d, J = 7.9 Hz, 1H), 3.91 (d, J = 7.3 Hz, 1H), 3.87 - 3.74 (m, 1H), 3.38 (d, J = 7.0 Hz, 1H), 3.06 (t, J = 10.6 Hz, 1H), 1.94 (t, J = 13.2 Hz, 2H), 1.62 - 1.43 (m, 2H), 1.39 (s, 9H). M / Z: 342, 344 [M-tBu+H], ESI+, RT = 1.21 min (S1).

[0138] Step 1.2: tert-butyl N-[(3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]tetrahydropyran-3-yl]carbamate [ka] A suspension of tert-butyl N-[(3R,6S)-6-[[(4-chlorobenzoyl)amino]carbamoyl]tetrahydropyran-3-yl]carbamate (372 mg, 0.673 mmol) and methoxycarbonyl-(triethylammonio)sulfonyl-azanilide (642 mg, 2.69 mmol) in dry THF (4 mL) was stirred at 120 °C for 10 minutes under microwave irradiation (normal absorption). The resulting solution was partitioned between water (25 mL) and EtOAc (25 mL), and the organic layer was washed with brine (25 mL), dried (MgSO), filtered, and concentrated in vacuo. The residual material was purified using flash chromatography on silica eluting with 1:0 to 0:1 heptane-EtOAc to give tert-butyl N-[(3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]tetrahydropyran-3-yl]carbamate (227 mg, 0.539 mmol, 80% yield) as an off-white powder. 1 H NMR (500 MHz, Chloroform-d) δ 8.04 - 7.97 (m, 2H), 7.52 - 7.45 (m, 2H), 4.72 (dd, J= 9.6, 3.0 Hz, 1H), 4.48 (s, 1H), 4.23 - 4.14 (m, 1H), 3.82 - 3.72 (m, 1H), 3.30 (t, J= 10.2 Hz, 1H), 2.32 - 2.10 (m, 2H), 1.58 (d, J= 18.1 Hz, 2H), 1.46 (s, 9H). M / Z: 324, 326 [M-tBu+H], ESI+, RT = 1.21 min (S1).

[0139] Scheme for Route 2 [ka]

[0140] Intermediate 2: 2-[(6-chloro-5-fluoro-3-pyridyl)oxy]acetic acid [ka] An aqueous solution of 2 M NaOH (12 mL, 24.7 mmol) was added to a solution of ethyl 2-[(6-chloro-5-fluoro-3-pyridyl)oxy]acetate (96%, 6.01 g, 24.7 mmol) in methanol (15 mL) at room temperature and stirred for 2 hours. The reaction mixture was concentrated and then acidified to pH 4 with 1 N HCl solution. The precipitated solid was filtered to give 2-[(6-chloro-5-fluoro-3-pyridyl)oxy]acetic acid (1.00 g, 4.67 mmol, 19% yield) as a beige solid. 1 H NMR (500 MHz, DMSO-d6) δ 8.06 (d, J = 2.6 Hz, 1H), 7.73 (dd, J = 10.4, 2.6 Hz, 1H), 4.82 (s, 2H). M / Z: 206, 208, ESI+, RT = 0.85 min (S1).

[0141] Step 2.1: Ethyl 2-[(6-chloro-5-fluoro-3-pyridyl)oxy]acetate [ka] Ethyl 2-bromoacetate (3.4 mL, 30.2 mmol) was added to a suspension of 6-chloro-5-fluoropyridin-3-ol (4.25 g, 28.8 mmol) and potassium carbonate (11.94 g, 86.4 mmol) in DMF (12 mL), stirred at 65 °C for 1 h, allowed to cool to room temperature, and allowed to stand at room temperature overnight. The reaction mixture was suspended in EtOAc (20 mL) and filtered. The filtrate was washed with water (50 mL), brine (50 mL), dried over NaSO, filtered, and evaporated to give ethyl 2-[(6-chloro-5-fluoro-3-pyridyl)oxy]acetate (6.01 g, 24.7 mmol, 86% yield) as a green solid. 1H NMR (500 MHz, Chloroform-d) δ 7.92 (d, J = 2.6 Hz, 1H), 7.08 (dd, J = 9.1, 2.6 Hz, 1H), 4.65 (s, 2H), 4.26 (q, J = 7.1 Hz, 2H), 1.29 (t, J = 7.1 Hz, 3H). M / Z: 234, 236 [M+1], ESI+, RT = 1.09 min (S1).

[0142] Scheme for Route 3 [ka]

[0143] Intermediate 3: tert-butyl N-[3R,6S)-6-(hydrazinecarbonyl)tetrahydropyran-3-yl]carbamate [ka] To a degassed solution of tert-butyl N-[(3R,6S)-6-(benzyloxycarbonylaminocarbamoyl)tetrahydropyran-3-yl]carbamate (950 mg, 2.41 mmol) in ethanol (25 mL) and EtOAc (15 mL) at room temperature, palladium on charcoal (10%, 95 mg, 0.089 mmol) was added, and the reaction mixture was stirred under an atmosphere of hydrogen for 3 hours. The reaction was quenched by switching the atmosphere to N2. The reaction mixture was warmed to near reflux and hot filtered through a pad of Celite®, washing thoroughly with ethanol. The filtrate was concentrated to dryness to give tert-butyl N-[(3R,6S)-6-(hydrazinecarbonyl)tetrahydropyran-3-yl]carbamate (678 mg, 2.46 mmol, 100% yield) as an off-white powder. 1H NMR (500 MHz, DMSO-d6) δ 8.86 (s, 1H), 6.80 (d, J = 7.7 Hz, 1H), 4.20 (s, 2H), 3.91 - 3.80 (m, 1H), 3.68 - 3.62 (m, 1H), 3.02 - 2.94 (m, 1H), 1.93 - 1.82 (m, 2H), 1.46 - 1.31 (m, 12H).

[0144] Step 3.1: tert-butyl N-[(3R,6S)-6-(benzyloxycarbonylaminocarbamoyl)tetrahydropyran-3-yl]carbamate [ka] To a solution of (2S,5R)-5-(tert-butoxycarbonylamino)tetrahydropyran-2-carboxylic acid (710 mg, 2.89 mmol) and DIPEA (1.0 mL, 5.79 mmol) in dry DMF (7 mL) was added HATU (1.21 g, 3.18 mmol). The solution was stirred for 10 minutes. Benzyl N-aminocarbamate A solution of tert-butyl N-[(3R,6S)-6-(benzyloxycarbonylaminocarbamoyl)tetrahydropyran-3-yl]carbamate (950 mg, 2.20 mmol, 76% yield) was then added in portions, and the reaction mixture was stirred at room temperature for 1 hour. The reaction was quenched with water (20 mL) and stirred vigorously for 10 minutes. The mixture was filtered to collect an off-white precipitate, which was further dried in a high vacuum oven to give tert-butyl N-[(3R,6S)-6-(benzyloxycarbonylaminocarbamoyl)tetrahydropyran-3-yl]carbamate (950 mg, 2.20 mmol, 76% yield) as an off-white powder. 1NMR (400MHz, DMSO-d6) δ 9.60 (s, 1H), 9.12 (s, 1H), 7.35 (d, J = 15.1 Hz, 5H), 6.82 (d, J = 7.1 Hz, 1H), 5.07 (s, 2H), 3.88 (d, J = 6.1 M / Z: 416 [M+Na], ESI+, RT = 1.09 min (S1).

[0145] Scheme for Route 4: [ka]

[0146] Intermediate 4: 2-(5-chloropyrazin-2-yl)oxyacetic acid [ka] 4 M hydrogen chloride in 1,4-dioxane (10 mL, 40.0 mmol) was added to tert-butyl 2-(5-chloropyrazin-2-yl)oxyacetate (269 mg, 1.09 mmol) at room temperature and stirred for 72 hours. The mixture was evaporated to dryness. The residue was purified by flash chromatography using a C18-12 g KP-Ultra SNAP cartridge eluting with a solution of MeCN (+0.1% formic acid) (10% to 100%) in water (+0.1% formic acid) to afford 2-(5-chloropyrazin-2-yl)oxyacetic acid (120 mg, 0.630 mmol, 58% yield) as a white solid. 1 H NMR (500 MHz, DMSO-d6) δ 8.36 (d, J = 1.3 Hz, 1H), 8.29 (d, J = 1.3 Hz, 1H), 4.89 (s, 2H). M / Z: 187, 189 [MH], ESI-, RT = 0.76 min (S1).

[0147] Step 4.1: tert-Butyl 2-(5-chloropyrazin-2-yl)oxyacetate [ka] To a solution of tert-butyl 2-hydroxyacetate (0.049 mL, 3.69 mmol) in dry DMF (5 mL) at room temperature, sodium hydride (89 mg, 3.69 mmol) was added portionwise over 5 min. Additional DMF (5 mL) was added to the suspension and stirred for 30 min. 2,5-Dichloropyrazine (500 mg, 3.36 mmol) was then added dropwise, and the reaction mixture was stirred at room temperature for 3 h. The reaction mixture was slowly diluted with water (50 mL) and extracted with EtOAc (2 × 30 mL). The combined organic layers were washed with brine (30 mL), dried over NaSO, filtered, and evaporated to dryness. The residue was purified using Method 1 to give tert-butyl 2-(5-chloropyrazin-2-yl)oxyacetate (269 mg, 1.09 mmol, 32% yield) as a white solid. 1 H NMR (500 MHz, Chloroform-d) δ 8.12 (d, J = 1.0 Hz, 1H), 8.05 (d, J = 1.0 Hz, 1H), 4.78 (s, 2H), 1.47 (s, 9H). M / Z: 245, 247 [M+H], ESI+, RT = 1.18 min (S1).

[0148] Scheme for Route 5: [ka]

[0149] Intermediate 5: 2-chloro-N-[(3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]tetrahydropyran-3-yl]acetamide [ka] A solution of [(3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]tetrahydropyran-3-yl]ammonium chloride (250 mg, 0.791 mmol) and DIPEA (0.28 mL, 1.58 mmol) in DMF (3 mL) was stirred for 5 minutes. After the reaction mixture was cooled to 0° C., 2-chloroacetyl chloride (89 mg, 0.791 mmol) in DMF (3 mL) was added. The reaction mixture was warmed to room temperature and stirred for 1.5 hours. Water (10 mL) was added, and the reaction mixture was filtered under vacuum and rinsed with water to give 2-chloro-N-[(3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]tetrahydropyran-3-yl]acetamide (146 mg, 0.344 mmol, 44% yield) as a brown solid. 1 H NMR (500 MHz, DMSO-d6) δ 8.27 (d, J = 7.6 Hz, 1H), 8.06 - 8.01 (m, 2H), 7.71 - 7.67 (m, 2H), 4.84 (dd, J = 10.6, 2.6 Hz, 1H), 4.06 (d, J = 1.3 Hz, 2H), 3.98 - 3.92 (m, 1H), 3.85 - 3.75 (m, 1H), 3.50-3.25 (m, 1H), 2.16 (dt, J = 10.5, 4.3 Hz, 1H), 2.08 - 1.96 (m, 2H), 1.72 - 1.62 (m, 1H). M / Z: 356, 358 [M+H], ESI+, RT = 1.03 min (S1).

[0150] Scheme for Route 6: [ka]

[0151] Intermediate 6: (2R,5S)-5-(tert-butoxycarbonylamino)tetrahydropyran-2-carboxylic acid [ka] A solution of tert-butyl N-[(3S,6R)-6-(hydroxymethyl)tetrahydropyran-3-yl]carbamate (657 mg, 2.84 mmol) in DCM (5 mL), acetonitrile (5 mL), and water (7 mL) was vigorously stirred while cooling to 0 °C. Sodium periodate (1.22 g, 5.68 mmol) and ruthenium(3+) trichloride (0.027 g, 0.13 mmol) were added, and the reaction was stirred at this temperature for 3 h. EtOAc (10 mL) was added, and the mixture was filtered. Methanol was added, and the solution was filtered. A solution of 10% sodium bisulfite (10 ml) was added, and the pH was adjusted to 2 with 1 M HCl. The aqueous layer was separated and extracted with EtOAc. The organic layers were combined, dried over MgSO4, and concentrated under reduced pressure. The residue was dissolved in saturated NaHCO3 (10 mL) and extracted with EtOAc (2 × 10 mL). The aqueous layer was acidified to pH 2 with 1 M HCl and extracted with EtOAc (4 × 10 mL), and the organic layers were combined, dried over MgSO and concentrated under reduced pressure. The residue was triturated with 1:2 TBME / heptane (100 mL), filtered and dried in vacuo to give (2R,5S)-5-(tert-butoxycarbonylamino)tetrahydropyran-2-carboxylic acid (375 mg, 1.53 mmol, 54% yield) as a yellow powder. 1 H NMR (400 MHz, Chloroform-d) δ 4.57 - 4.15 (m, 2H), 4.13 - 3.85 (m, 2H), 3.79 - 3.39 (m, 1H), 3.15 (t,J= 10.6 Hz, 1H), 2.27 - 2.03 (m, 2H), 1.87 - 1.62 (m, 1H), 1.44 (s, 10H).

[0152] Step 6.1: Methyl (2R)-2-(tert-butoxycarbonylamino)-3-iodo-propanoate [ka] Imidazole (4.27 g, 62.8 mmol) was added to a solution of triphenylphosphane (16.46 g, 62.8 mmol) in DCM (200 mL) at room temperature, and after complete dissolution, cooled to 0 °C under a N atmosphere. Molecular iodine (15.93 g, 62.8 mmol) was added in small portions over 20 min. The solution was warmed to room temperature, stirred for 10 min, and cooled back to 0 °C. A solution of methyl (2{S})-2-(tert-butoxycarbonylamino)-3-hydroxy-propanoate (10.59 g, 48.3 mmol) in DCM (50 mL) was added dropwise over 1 h. The reaction was stirred at 0 °C for 1 h, allowed to warm to room temperature, and stirred for an additional 1.5 h. The reaction mixture was filtered through a silica plug (75 g) eluting with 1:1 ether:heptane, and the solvent was evaporated. The residue was purified by chromatography on silica gel eluting with 0-30% TBME in heptane to give a clear oil. After crystallization from heptane, the solid was collected by filtration and dried in vacuo to give methyl (2R)-2-(tert-butoxycarbonylamino)-3-iodo-propanoate (11.46 g, 33.1 mmol, 69% yield). 1 H NMR (500 MHz, Chloroform-d) δ 5.34 (d, J= 5.9 Hz, 1H), 4.56 - 4.46 (m, 1H), 3.80 (s, 3H), 3.63 - 3.49 (m, 2H), 1.46 (s, 9H).

[0153] Step 6.2: Methyl (2S)-2-(tert-butoxycarbonylamino)hex-5-enoate [ka] Zinc (1.96 g, 30.0 mmol) and molecular iodine (76 mg, 0.299 mmol) were added to a three-neck flask equipped with a thermometer. The flask was evacuated and heated with a heat gun for 10 minutes, then flushed with N2; the process was repeated twice. After cooling to room temperature, dry DMF (1 mL) was added and the slurry was cooled to 0 °C. A solution of methyl (2{R})-2-(tert-butoxycarbonylamino)-3-iodo-propanoate (3.29 g, 10.0 mmol) in DMF (6.5 mL) was added dropwise over 10 minutes, and the reaction mixture was stirred at room temperature for 1 hour.

[0154] A second three-neck flask equipped with a thermometer was charged with bromocopper methylsulfanylmethane (207 mg, 1.00 mmol) and gently heated with a heat gun under vacuum until the color changed from off-white to pale green. After cooling to room temperature, DMF (6.5 mL) and 3-chloroprop-1-ene (0.81 mL, 10.0 mmol) were added. The flask was cooled to -15 °C, and the zinc reagent was added dropwise. The reaction mixture was allowed to warm to room temperature and stirred for 18 h. EtOAc (75 mL) was added, and the mixture was stirred for 15 min, diluted with additional EtOAc (75 mL), washed with 5% NaSO (2 × 25 mL), water (2 × 25 mL), brine (25 mL), dried over NaSO, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel eluting with 0-50% TBME in heptane to give methyl (2S)-2-(tert-butoxycarbonylamino)hex-5-enoate (1.96 g, 7.67 mmol, 77% yield) as a clear oil. 1H NMR (500 MHz, Chloroform-d) δ 5.79 (ddt, J= 16.9, 10.2, 6.6 Hz, 1H), 5.08 - 4.95 (m, 3H), 4.36 - 4.27 (m, 1H), 3.74 (s, 3H), 2.17 - 2.05 (m, 2H), 1.90 (dq, J= 13.5, 7.4 Hz, 1H), 1.71 (dq, J= 14.4, 8.0 Hz, 1H), 1.44 (s, 9H).

[0155] Step 6.3: tert-Butyl N-[(1S)-1-(hydroxymethyl)pent-4-enyl]carbamate [ka] To a suspension of lithium borohydride (0.17 g, 7.67 mmol) in THF (43 mL) at room temperature under a N atmosphere was added a solution of methyl (2S)-2-(tert-butoxycarbonylamino)hex-5-enoate (95%, 1.96 g, 7.67 mmol) in THF (14 mL), and the resulting solution was stirred at room temperature for 18 h. Water was added, the mixture was extracted with EtOAc, and the organic layers were combined, washed with brine, dried over NaSO, and concentrated under reduced pressure to give tert-butyl N-[(1S)-1-(hydroxymethyl)pent-4-enyl]carbamate (1.85 g, 7.73 mmol, 100% yield) as a colorless oil. 1 H NMR (500 MHz, Chloroform-d) δ 5.86 - 5.76 (m, 1H), 5.07 - 4.95 (m, 2H), 4.63 (s, 1H), 3.66 (s, 2H), 3.56 (dd, J= 10.1, 5.0 Hz, 1H), 2.20 - 2.06 (m, J= 7.3, 6.8 Hz, 2H), 1.68 - 1.48 (m, 3H), 1.45 (s, 9H).

[0156] Step 6.4: tert-Butyl N-[(1S)-1-(hydroxymethyl)-3-(oxiran-2-yl)propyl]carbamate [ka] A solution of tert-butyl N-[(1S)-1-(hydroxymethyl)pent-4-enyl]carbamate (1.85 g, 7.73 mmol) in DCM (30 mL) was added to a solution of potassium phosphate (4.04 g, 23.2 mmol) in water (40 mL) and stirred vigorously at room temperature. 3-Chlorobenzenecarboperoxoic acid (1.78 g, 7.73 mmol) was added and stirring continued for 18 hours. The layers were separated and extracted with aqueous DCM (50 mL). The organic layers were combined, dried over Na2SO4, and concentrated in vacuo. The residue was purified by chromatography on silica gel eluting with 0 to 100% EtOAc in heptane to give tert-butyl N-[(1S)-1-(hydroxymethyl)-3-(oxiran-2-yl)propyl]carbamate (1.32 g, 4.58 mmol, 59% yield) as a clear oil. 1 H NMR (500 MHz, Chloroform-d) δ 4.72 (d, J= 31.2 Hz, 1H), 3.72 - 3.50 (m, 3H), 2.98 - 2.90 (m, 1H), 2.57 - 2.43 (m, 1H), 2.45 - 2.20 (m, 1H), 1.80 - 1.51 (m, 4H), 1.44 (s, 10H).

[0157] Step 6.5: tert-Butyl N-[(3S,6R)-6-(hydroxymethyl)tetrahydropyran-3-yl]carbamate [ka] (7,7-Dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methanesulfonate (262 mg, 1.13 mmol) was added to a solution of tert-butyl N-[(1S)-1-(hydroxymethyl)-3-(oxiran-2-yl)propyl]carbamate (3.48 g, 11.3 mmol) in DCM (75 mL), and the resulting solution was stirred at room temperature for 18 h. The reaction mixture was poured into an aqueous solution of NaHCO3, and the layers were separated. The organic layer was dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with 0 to 100% EtOAc in heptane to give an off-white powder. The solid was triturated with heptane to give tert-butyl N-[(3S,6R)-6-(hydroxymethyl)tetrahydropyran-3-yl]carbamate (662 mg, 2.86 mmol, 25% yield) as an off-white powder. 1 H NMR (500 MHz, Chloroform-d) δ 4.26 (s, 1H), 4.11 (ddd, J = 10.7, 4.7, 2.1 Hz, 1H), 3.60 (ddd, J = 11.2, 7.9, 3.1 Hz, 2H), 3.51 (ddd, J = 11.5, 7.1, 4.5 Hz, 1H), 3.36 (dtd, J = 10.3, 5.5, 2.7 Hz, 1H), 3.02 (t, J = 10.7 Hz, 1H), 2.16 - 1.96 (m, 2H), 1.51 - 1.36 (m, 10H), 1.29 (qd, J = 12.5, 4.2 Hz, 1H)

[0158] Scheme for Route 7 [ka]

[0159] Intermediate 7: Lithium 2-[(5-fluoro-6-methyl-3-pyridyl)oxy]acetate [ka] To a solution of ethyl 2-[(5-fluoro-6-methyl-3-pyridyl)oxy]acetate (0.50 g, 2.35 mmol) in methanol (5 mL) at room temperature was added 2 M hydroxylithium (2.3 mL, 4.69 mmol), stirred overnight at room temperature, and then evaporated to dryness. The solid was suspended in acetonitrile (10 mL) and evaporated to dryness to give lithium 2-[(5-fluoro-6-methyl-3-pyridyl)oxy]acetate (630 mg, 2.34 mmol, 100% yield) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ 8.01 - 7.84 (m, 1H), 7.08 - 7.00 (m, 1H), 4.20 - 4.11 (m, 2H), 3.20 - 3.13 (m, 1H), 2.35 - 2.29 (m, 3H). M / Z: 186 [M+H]+, RT = 0.4-0.6 min (S4).

[0160] Step 7.1: Ethyl 2-[(5-fluoro-6-methyl-3-pyridyl)oxy]acetate [ka] To a degassed solution of ethyl 2-[(6-chloro-5-fluoro-3-pyridyl)oxy]acetate (97%, 2.60 g, 10.8 mmol) in anhydrous THF (30 mL) at room temperature under a nitrogen atmosphere, palladium triphenylphosphane (0.80 g, 0.692 mmol) was added and stirred. 2 M chloro(methyl)zinc in THF (6.5 mL, 13.0 mmol) was then added and stirred for 5 minutes. The reaction mixture was heated to 75° C., stirred overnight, and allowed to cool to room temperature. The reaction mixture was quenched with ammonium chloride solution (20 mL), diluted with water (100 mL), and extracted with EtOAc (2×50 mL). The organic layer was dried over sodium sulfate, filtered, and evaporated to dryness. Purification by flash chromatography (Biotage Isolera, C18 120 g KP-Ultra SNAP cartridge) eluting with a solution of MeCN (+0.1% formic acid) in water (+0.1% formic acid) (10% to 100%), followed by evaporation, gave ethyl 2-[(5-fluoro-6-methyl-3-pyridyl)oxy]acetate (1.69 g, 7.69 mmol, 71% yield) as an off-white solid. 1 H NMR (400 MHz, Chloroform-d) δ 8.05 (d, J = 2.4 Hz, 1H), 6.94 (dd, J = 10.4, 2.5 Hz, 1H), 4.63 (s, 2H), 4.27 (q, J = 7.1 Hz, 2H), 2.45 (d, J = 2.9 Hz, 3H), 1.30 (t, J = 7.1 Hz, 3H). M / Z: 214 [M+H]+, RT = 0.98 (S1).

[0161] Scheme for Route 8: [ka]

[0162] [Example 1] 2-(4-chloro-3-fluoro-phenoxy)-N-[(3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]tetrahydropyran-3-yl]acetamide To a solution of [(3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]tetrahydropyran-3-yl]ammonium chloride (78 mg, 0.241 mmol) in DCM (1.5 mL) was added DIPEA (0.17 mL, 0.964 mmol) followed by a solution of 2-(4-chloro-3-fluoro-phenoxy)acetyl chloride (0.11 g, 0.482 mmol) in DCM (1 mL) dropwise at room temperature. After stirring for 5 minutes, the reaction mixture was diluted with 1 M aqueous hydrogen chloride solution and DCM. The organic layer was isolated, washed successively with 1 M NaOH solution and brine, dried (MgSO), filtered, and concentrated in vacuo. The residual material was purified by column chromatography (eluting with heptane-EtOAc, 1:0 to 0:1, silica gel) to give 2-(4-chloro-3-fluoro-phenoxy)-N-[(3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]tetrahydropyran-3-yl]acetamide (106 mg, 0.22 mmol, 92% yield) as an off-white solid. 1 H NMR (500 MHz, DMSO-d6) δ 8.12 (d, J = 7.8 Hz, 1H), 8.00 - 8.06 (m, 2H), 7.67 - 7.73 (m, 2H), 7.51 (t, J = 8.9 Hz, 1H), 7.09 (dd, J = 11.4, 2.8 Hz, 1H), 6.83 - 6.91 (m, 1H), 4.82 (dd, J = 10.7, 2.6 Hz, 1H), 4.56 (s, 2H), 3.84 - 4.00 (m, 2H), 3.38 (t, J = 10.2 Hz, 1H), 2.12 - 2.22 (m, 1H), 1.95 - 2.08 (m, 2H), 1.68 - 1.80 (m, 1H). M / Z: 466[M+H], ESI+, RT = 4.20 min (S1).

[0163] Following general route 8, the compounds in Table 1 were synthesized using the corresponding intermediates as exemplified by Example 1.

[0164] [Table 1] [Table 2] [Table 3]

[0165] Scheme for Route 9: [ka]

[0166] [Example 7] 2-[(6-chloro-5-fluoro-3-pyridyl)oxy]-N-[(3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]tetrahydropyran-3-yl]acetamide To a solution of 2-[(6-chloro-5-fluoro-3-pyridyl)oxy]acetic acid (36 mg, 0.174 mmol), HATU (66 mg, 0.174 mmol), and N-ethyl-N-isopropyl-propan-2-amine (0.055 mL, 0.316 mmol) in dry DMF (2 mL) was added [(3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]tetrahydropyran-3-yl]ammonium chloride (50 mg, 0.158 mmol). The mixture was stirred at room temperature for 60 minutes. The reaction mixture was then diluted with EtOAc, washed with water, followed by a saturated aqueous solution of NaHCO3 (20 mL), dried over sodium sulfate, filtered, and evaporated to dryness. The solid was then purified by preparative HPLC (Method 1) to give 2-[(6-chloro-5-fluoro-3-pyridyl)oxy]-N-[(3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]tetrahydropyran-3-yl]acetamide (37 mg, 0.0784 mmol, 50% yield) as a white powder. 1HNMR(500MHz, DMSO-d6) δ = 8.17 (d, J =7.8, 1H), 8.08 (d, J =2.6, 1H), 8.06 - 8.01 (m, 2H), 7.71 (dd, J =10.3, 2.6, 1H), 7.70 - 7.66 (m, 2H), 4.87 - 4.76 (m, 1H), 4.67 (d, J =1.9, 2H), 3.97 - 3.91 (m, 1H), 3.92 - 3.84 (m, 1H), 3.40 - 3.37 (m, 1H), 2.16 (d, J =13.7, 1H), 2.10 - 1.95 (m, 2H), 1.77 - 1.67 (m, 1H). M / Z: 467, 469 [M+H], ESI+, RT = 3.35 min (S2).

[0167] Following general route 9, the compounds in Table 2 were synthesized using the corresponding intermediates as exemplified by Example 7.

[0168] [Table 4] [Table 5] [Table 6] [Table 7]

[0169] Scheme for Route 10 [ka]

[0170] [Example 18] N-[3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]tetrahydropyran-3-yl]-2-[[6-(trifluoromethyl)-3-pyridyl]oxy]acetamide: [ka] A solution of 2-chloro-N-[(3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]tetrahydropyran-3-yl]acetamide (84%, 70 mg, 0.165 mmol), dipotassium carbonate (46 mg, 0.330 mmol), sodium iodide (37 mg, 0.248 mmol), and 6-(trifluoromethyl)pyridin-3-ol (27 mg, 0.165 mmol) in dry DMF (1 mL) was stirred under N at 40° C. for 4 h. Water was added, and the formed precipitate was filtered under vacuum. The residue was purified by column chromatography on a silica gel column using EtOAc / heptane (40-100%) as eluent to give N-[(3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]tetrahydropyran-3-yl]-2-[[6-(trifluoromethyl)-3-pyridyl]oxy]acetamide (41 mg, 0.082 mmol, 50% yield) as a white solid. 1 H NMR (500 MHz, DMSO-d6) δ 8.48 (d, J = 2.8 Hz, 1H), 8.23 ​​(d, J = 7.8 Hz, 1H), 8.06 - 8.01 (m, 2H), 7.88 (d, J = 8.7 Hz, 1H), 7.71 - 7.66 (m, 2H), 7.58 (dd, J = 8.7, 2.8 Hz, 1H), 4.83 (dd, J = 10.7, 2.5 Hz, 1H), 4.74 (d, J = 1.8 Hz, 2H), 3.98 - 3.93 (m, 1H), 3.93 - 3.85 (m, 1H), 3.40 (s, 1H), 2.17 (dt, J = 10.2, 2.5 Hz, 1H), 2.08 - 1.97 (m, 2H), 1.78 - 1.69 (m, 1H). M / Z: 483, 485 [M+H]+, RT = 3.37 (S2).

[0171] Following general route 10, the compounds in Table 3 were synthesized using the corresponding intermediates as exemplified by Example 18.

[0172] [Table 8]

[0173] II. Biological Assays HEK-ATF4 high-content imaging assay Example compounds were tested in a HEK-ATF4 high-content imaging assay to determine their pharmacological efficacy in preventing tunicamycin-induced ISR. Wild-type HEK293 cells were plated in growth medium (DMEM / F12, 10% FBS, 2 mM L-glutamine, 100 U / mL penicillin-100 μg / mL streptomycin) at a density of 12,000 cells per well in a 384-well imaging assay plate and incubated at 37°C and 5% CO2. After 24 hours, the medium was changed to 50 μl of assay medium (DMEM / F12, 0.3% FBS, 2 mM L-glutamine, 100 U / mL penicillin-100 μg / mL streptomycin) per well. Example compounds were serially diluted in dimethyl sulfoxide (DMSO) and spotted into the intermediate plate. Prediluted in assay medium containing 3.3 μM tunicamycin, resulting in an 11-fold excess of the final assay concentration. In addition to the example compound test area, the plate also contained multiple control wells for assay normalization purposes: wells containing tunicamycin but no example compound (high control), as well as wells containing neither example compound nor tunicamycin (low control). The assay was initiated by transferring 5 μl from the intermediate plate into the assay plate, followed by incubation for 6 hours at 37°C and 5% CO2. Cells were subsequently fixed (4% PFA in PBS, 20 minutes at room temperature) and subjected to indirect ATF4 immunofluorescence staining (primary antibody: rabbit anti-ATF4, clone D4B8, Cell Signaling Technologies; secondary antibody: Alexa Fluor 488 goat anti-rabbit IgG (H+L), Thermofisher Scientific). Nuclei were stained using Hoechst dye (Thermofisher Scientific), and plates were imaged on an Opera Phenix High Content Imaging Platform equipped with 405 nm and 488 nm excitation. Finally, images were analyzed using a script-based algorithm. The primary readout, HEK-ATF4, monitored the ratio of ATF4 signal between the nucleus and cytoplasm.Tunicamycin induced an increase in the overall ATF4 ratio signal, which was prevented by ISR-modulating example compounds. In addition, HEK-CellCount readings were derived from counting the number of stained nuclei corresponding to healthy cells. This reading served as an internal toxicity control. Example compounds herein did not produce a significant decrease in CellCount.

[0174] The activities of the tested example compounds are provided below in Table T5: +++=IC 50 1–500 nM; ++=IC 50 >500~2000nM;+=IC50 >2000~15000nM.

[0175] [Table 9]

[0176] reference (1) Pakos-Zebrucka K, Koryga I, Mnich K, Ljujic M, Samali A, Gorman AM. The integrated stress response. EMBO Rep. 2016 Oct;17(10):1374-1395. Epub 2016 Sep 14. (2) Wek RC, Jiang HY, Anthony TG. Coping with stress: eIF2 kinases and translational control. Biochem Soc Trans. 2006 Feb;34(Pt 1):7-11. (3) Donnelly N, Gorman AM, Gupta S, Samali A. The eIF2alpha kinases: their structures and functions. Cell Mol Life Sci. 201 3Oct;70(19):3493-511 (4) Jackson RJ, Hellen CU, Pestova TV. The mechanism of eukaryotic translation initiation and principles of its regulation. Nat Rev Mol Cell Biol. 2010 Feb;11(2):113-27 (5) Lomakin IB, Steitz TA. The initiation of mammalian protein synthesis and mRNA scanning mechanism. Nature. 2013 Aug 15;500(7462):307-11 (6) Pain VM. Initiation of protein synthesis in eukaryotic cells. Eur J Biochem. 1996 Mar 15;236(3):747-71 (7) Pavitt GD. Regulation of translation initiation factor eIF2B at the hub of the integrated stress response. Wiley Interdiscip Rev RNA. 2018 Nov;9(6):e1491. (8) Krishnamoorthy T, Pavitt GD, Zhang F, Dever TE, Hinnebusch AG. Tight binding of the phosphorylated alpha subunit of initiation factor 2 (eIF2alpha) to the regulatory subunits of guanine nucleotide exchange factor eIF2B is required for inhibition of translation initiation. Mol Cell Biol. 2001 Aug;21(15):5018-30. (9) Hinnebusch, A. G., Ivanov, I. P., & Sonenberg, N. (2016). Translational control by 5’-untranslated regions of eukaryotic mRNAs. Science, 352(6292), 1413 -1416. (10) Young, S. K., & Wek, R. C. (2016). Upstream open reading frames differentially regulate gene-specific translation in the integrated stress response. The Journal of Biological Chemistry, 291(33), 16927 -16935. (11) Lin JH, Li H, Zhang Y, Ron D, Walter P (2009) Divergent effects of PERK and IRE1 signaling on cell viability. PLoS ONE 4: e4170 (12) Tabas I, Ron D. Nat Cell Biol. 2011 Mar;13(3):184-90. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. (13) Shore GC, Papa FR, Oakes SA. Curr Opin Cell Biol. 2011 Apr;23(2):143-9. Signaling cell death from the endoplasmic reticulum stress response. (14) Bi M, Naczki C, Koritzinsky M, Fels D, Blais J, Hu N, Harding H, Novoa I, Varia M, Raleigh J, Scheuner D, Kaufman RJ, Bell J, Ron D, Wouters BG, Koumenis C. EMBO J. 2005 Oct 5;24(19):3470-81 ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth. (15) Bobrovnikova-Marjon E, Grigoriadou C, Pytel D, Zhang F, Ye J, Koumenis C, Cavener D, Diehl JA. Oncogene. 2010 Jul 8;29(27):3881-95 PERK promotes cancer cell proliferation and tumor growth by limiting oxidative DNA damage. (16) Avivar-Valderas A, Salas E, Bobrovnikova-Marjon E, Diehl JA, Nagi C, Debnath J, Aguirre-Ghiso JA. Mol Cell Biol. 2011 Sep;31(17):3616-29. PERK integrates autophagy and oxidative stress responses to promote survival during extracellular matrix detachment. (17) Blais, J. D.; Addison, C. L.; Edge, R.; Falls, T.; Zhao, H.; Kishore, W.; Koumenis, C.; Harding, H. P.; Ron, D.; Holcik, M.; Bell, J. C. Mol. Cell. Biol. 2006, 26, 9517-9532.PERK-dependent translational regulation promotes tumor cell adaptation and angiogenesis in response to hypoxic stress. (18) Taalab YM, Ibrahim N, Maher A, Hassan M, Mohamed W, Moustafa AA, Salama M, Johar D, Bernstein L. Rev Neurosci. 2018 Jun 27;29(4):387-415. Mechanisms of disordered neurodegenerative function: concepts and facts about the different roles of the protein kinase RNA-like endoplasmic reticulum kinase (PERK). (19) Remondelli P, Renna M. Front Mol Neurosci. 2017 Jun 16;10:187. The Endoplasmic Reticulum Unfolded Protein Response in Neurodegenerative Disorders and Its Potential Therapeutic Significance. (20) Halliday M, Mallucci GR. Neuropathol Appl Neurobiol. 2015 Jun;41(4):414-27.Review: Modulating the unfolded protein response to prevent neurodegeneration and enhance memory. (21) Halliday M, Radford H, Sekine Y, Moreno J, Verity N, le Quesne J, Ortori CA, Barrett DA, Fromont C, Fischer PM, Harding HP, Ron D, Mallucci GR. Cell Death Dis. 2015 Mar 5;6:e1672.Partial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity. (22) Moreno JA, Radford H, Peretti D, Steinert JR, Verity N, Martin MG, Halliday M, Morgan J, Dinsdale D, Ortori CA, Barrett DA, Tsaytler P, Bertolotti A, Willis AE, Bushell M, Mallucci GR. Nature 2012; 485: 507-11. Sustained translational repression by eIF2alpha-P mediates prion neurodegeneration. (23) Skopkova M, Hennig F, Shin BS, Turner CE, Stanikova D, Brennerova K, Stanik J, Fischer U, Henden L, Muller U, Steinberger D, Leshinsky-Silver E, Bottani A, Kurdiova T, Ukropec J, Nyitrayova O, Kolnikova M, Klimes I, Klimes I, Kim, Bah, Hass, SA JR, Lotspeich-Cole LE, Gasperikova D, Dever TE, Kalscheuer VM. Hum Mutat. 2017 Apr;38(4):409-425. EIF2S3 Mutations Associated with Severe X-Linked Intellectual Disability Syndrome MEHMO. (24) Hamilton EMC, van der Lei HDW, Vermeulen G, Gerver JAM, Lourenco CM, Naidu S, Mierzewska H, ​​Gemke RJBJ, de Vet HCW, Uitdehaag BMJ, Lissenberg-Witte BI; VWM Research Group, van der Knaap MS. Ann Neurol. 2018 Aug;84(2):274-288. Natural History of Vanishing White Matter. (25) Bugiani M, Vuong C, Breur M, van der Knaap MS. Brain Pathol. 2018 May;28(3):408-421. Vanishing white matter: a leukodystrophy due to astrocytic dysfunction. (26) Wong YL, LeBon L, Edalji R, Lim HB, Sun C, Sidrauski C. Elife. 2018 Feb 28;7. The small molecule ISRIB rescues the stability and activity of Vanishing White Matter Disease eIF2B mutant complexes. (27) Wong YL, LeBon L, Basso AM, Kohlhaas KL, Nikkel AL, Robb HM, Donnelly-Roberts DL, Prakash J, Swensen AM, Rubinstein ND, Krishnan S, McAllister FE, Haste NV, O'Brien JJ, Roy M, Ireland A, Frost JM, Shi L, Riedmaier S, Martin K, Dart MJ, Sidrauski C. Elife. 2019 Jan 9;8. eIF2B activator prevents neurological defects caused by a chronic integrated stress response. (28) Nguyen HG, Conn CS, Kye Y, Xue L, Forester CM, Cowan JE, Hsieh AC, Cunningham JT, Truillet C, Tameire F, Evans MJ, Evans CP, Yang JC, Hann B, Koumenis C, Walter P, Carroll PR, Ruggero D. Sci Transl Med. 2018 May 2;10(439). Development of a stress response therapy targeting aggressive prostate cancer.

Claims

1. Formula (I) [Case 1] or a pharma- ceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof. (In the formula, A 1 is C 5 Cycloalkylene, C 5 cycloalkenylene, or a nitrogen ring atom-containing 5-membered heterocyclene, where A 1 represents one or more R 4 optionally substituted with; Each R 4 are independently halogen, CN, OR 5 , oxo (=O) where the ring is at least partially saturated, or C 1~6 alkyl, where C 1~6 The alkyl is optionally substituted with one or more halogens which may be the same or different; R 5 is H or C 1~6 alkyl, where C 1~6 The alkyl is optionally substituted with one or more halogens which may be the same or different; A 2 is phenyl or a 5- to 6-membered aromatic heterocyclyl, where A 2 represents one or more R 6 optionally substituted with; Each R 6 are independently OH, O(C 1~6 Alkyl), halogen, CN, cyclopropyl, C 1~6 Alkyl, C 2~6 Alkenyl or C 2~6 alkynyl, where cyclopropyl, C 1~6 Alkyl, C 2~6 Alkenyl and C 2~6 alkynyl is optionally substituted with one or more halogens which may be the same or different; or Two R's 6are connected to the ring A together with the atom to which they are attached. 2a Forming A 2a is phenyl, C 3~7 cycloalkyl, or 3- to 7-membered heterocyclyl, where A 2a represents one or more R 7 optionally substituted with; Each R 7 is independent, C 1~6 Alkyl, C 2~6 Alkenyl or C 2~6 alkynyl, where C 1~6 Alkyl, C 2~6 Alkenyl and C 2~6 alkynyl is optionally substituted with one or more halogens which may be the same or different; R 1 is H or C 1~4 alkyl, where C 1~4 The alkyl is optionally substituted with one or more halogens which may be the same or different; R 2 is H or C 1~4 alkyl, where C 1~4 The alkyl is optionally substituted with one or more halogens which may be the same or different; R 3 A 3 or R 2 and R 3 are connected to one or more R 8 forming a 3,4-dihydro-2H-1-benzopyran ring optionally substituted with A 3 is phenyl or a 5- to 6-membered aromatic heterocyclyl, where A 3 represents one or more R 8 optionally substituted with; Each R 8 are independently halogen, CN, C(O)OR 9 , OR 9, C(O)R 9 , C(O)N(R 9 R 9a ), S(O) 2 N (R 9 R 9a ), S(O)N(R 9 R 9a ), S(O) 2 R 9 , S(O)R 9 , N(R 9 ) S (O) 2 N (R 9a R 9b ), S.R. 9 , N(R 9 R 9a ), NO 2 , O.C.(O)R 9 , N(R 9 ) C(O)R 9a , N(R 9 ) S (O) 2 R 9a , N(R 9 ) S(O)R 9a , N(R 9 ) C(O)OR 9a , N(R 9 ) C(O)N(R 9a R 9b ), OC(O)N(R 9 R 9a ), C 1~6 Alkyl, C 2~6 Alkenyl, or C 2~6 alkynyl, where C 1~6 Alkyl, C 2~6 Alkenyl and C 2~6 Alkynyl is one or more R 10 optionally substituted with; R 9 , R 9a , R 9b is H, C 1~6 Alkyl, C 2~6 Alkenyl and C 2~6 alkynyl, wherein C 1~6 Alkyl, C 2~6 Alkenyl and C 2~6alkynyl is optionally substituted with one or more halogens which may be the same or different; Each R 10 are independently halogen, CN, C(O)OR 11 , OR 11 , C(O)R 11 , C(O)N(R 11 R 11a ), S(O) 2 N (R 11 R 11a ), S(O)N(R 11 R 11a ), S(O) 2 R 11 , S(O)R 11 , N(R 11 ) S (O) 2 N (R 11a R 11b ), S.R. 11 , N(R 11 R 11a ), NO 2 , O.C.(O)R 11 , N(R 11 ) C(O)R 11a , N(R 11 ) S.O. 2 R 11a , N(R 11 ) S(O)R 11a , N(R 11 ) C(O)N(R 11a R 11b ), N(R 11 ) C(O)OR 11a , or OC(O)N(R 11 R 11a ) and R 11 , R 11a , R 11b is H, C 1~6 Alkyl, C 2~6 Alkenyl and C 2~6 alkynyl, wherein C 1~6 Alkyl, C 2~6 Alkenyl and C 2~6 The alkynyl is optionally substituted with one or more halogens which may be the same or different.

2. The compound of claim 1, or a pharma- ceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein R1 is H.

3. A 1 is a nitrogen ring atom-containing 5-membered heterocyclene; A 1 represents one or more R 4 3. The compound of claim 1 or 2, or a pharma- ceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, optionally substituted with

4. A 1 is a nitrogen ring atom-containing 5-membered heterocyclene selected from the group of divalent heterocycles consisting of oxadiazole, imidazole, imidazolidine, pyrazole and triazole; A 1 represents one or more R 4 4. The compound of claim 1 , or a pharma- ceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, optionally substituted with:

5. The compound of claim 4, or a pharma- ceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A1 is oxadiazole.

6. A 1 is unsubstituted or has one or two identical or different R 4 6. The compound of claim 1 , wherein R is substituted with R 1 or a pharma- ceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof.

7. The compound of claim 6, or a pharma- ceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A1 is unsubstituted.

8. R 4 8. The compound of claim 1 , or a pharma- ceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein: is oxo, the ring being at least partially saturated.

9. A 1 teeth, [chemical 2] 9. The compound of any one of claims 1 to 8, wherein:

10. A 2 is phenyl, pyridyl, pyrazinyl, pyridazinyl, pyrazolyl or 1,2,4-oxadiazolyl; A 2 represents one or more R 6 10. The compound of any one of claims 1 to 9, or a pharma- ceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, optionally substituted with:

11. A 2 is phenyl, pyridyl, pyrazinyl or pyridazinyl; A 2 represents one or more R 6 11. The compound of any one of claims 1 to 10, or a pharma- ceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, optionally substituted with:

12. A 2 is one or two R 6 12. The compound of claim 1 , wherein the compound is substituted with:

13. Each R 6 are independently F, Cl, CF 3 , O.C.H. 3 , C.H. 3 , C.H. 2 CH 3 13. The compound of any one of claims 1 to 12, wherein R is 1, 2, 3, 4, 5, 6, or 7, or a pharma- ceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof.

14. R 2is H, or a pharma- ceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof.

15. R 3 A 3 15. The compound of any one of claims 1 to 14, wherein:

16. A 3 is phenyl, pyridyl or pyrazinyl; A 3 represents one or more R 8 16. The compound of any one of claims 1 to 15, or a pharma- ceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, optionally substituted with:

17. A 3 is one or two R 8 17. The compound of any one of claims 1 to 16, or a pharma- ceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein R is substituted with R.

18. R 2 and R 3 are connected to form a dihydrobenzopyran ring, wherein the ring is joined to one or more of the same or different R 8 14. The compound of any one of claims 1 to 13, or a pharma- ceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, optionally substituted with:

19. The compound of claim 18, or a pharma- ceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, wherein R2 and R3 are connected to form a dihydrobenzopyran ring, wherein the ring is substituted with one or two R8s, which are the same or different.

20. R 8 are independently F, Cl, CF 3 , CH=O, CH 2 OH or CH 3 20. The compound of any one of claims 1 to 19, wherein:

21. 2-(4-chloro-3-fluorophenoxy)-N-[(3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]oxan-3-yl]acetamide, 2-(4-chlorophenoxy)-N-[(3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]oxan-3-yl]acetamide, 2-(4-chloro-3-fluorophenoxy)-N-[(3R,6S)-6-{5-[6-(trifluoromethyl)pyridin-3-yl]-1,3,4-oxadiazol-2-yl}oxan-3-yl]acetamide, 2-(4-chloro-3-fluorophenoxy)-N-[(3S,6R)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]oxan-3-yl]acetamide, 2-(4-chloro-3-fluorophenoxy)-N-[(3R,6S)-6-[5-(6-cyclopropylpyridin-3-yl)-1,3,4-oxadiazol-2-yl]oxan-3-yl]acetamide, 2-(4-chloro-3-fluorophenoxy)-N-[(3R,6S)-6-[5-(6-ethylpyridin-3-yl)-1,3,4-oxadiazol-2-yl]oxan-3-yl]acetamide, 2-[(6-chloro-5-fluoropyridin-3-yl)oxy]-N-[(3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]oxan-3-yl]acetamide, N-[(3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]oxan-3-yl]-2-{[2-(trifluoromethyl)pyridin-4-yl]oxy}acetamide, N-[(3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]oxan-3-yl]-2-[(6-chloropyridin-3-yl)oxy]acetamide, N-[(3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]oxan-3-yl]-2-[(5-fluoro-6-methylpyridin-3-yl)oxy]acetamide, 2-[(6-chloro-5-fluoropyridin-3-yl)oxy]-N-[(3R,6S)-6-[5-(6-chloropyridin-3-yl)-1,3,4-oxadiazol-2-yl]oxan-3-yl]acetamide, N-[(3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]oxan-3-yl]-2-[(6-methylpyridin-3-yl)oxy]acetamide, N-[(3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]oxan-3-yl]-2-[(5-chloropyrazin-2-yl)oxy]acetamide, N-[(3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]oxan-3-yl]-2-[(2-chloropyrimidin-5-yl)oxy]acetamide, 2-[(5-chloro-6-methylpyridin-3-yl)oxy]-N-[(3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]oxan-3-yl]acetamide, 2-(4-chloro-3-fluorophenoxy)-N-[(3R,6S)-6-{5-[5-(trifluoromethyl)pyridin-3-yl]-1,3,4-oxadiazol-2-yl}oxan-3-yl]acetamide, 2-(4-chloro-3-fluorophenoxy)-N-[(3R,6S)-6-{5-[2-(trifluoromethyl)pyridin-4-yl]-1,3,4-oxadiazol-2-yl}oxan-3-yl]acetamide, N-[3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]tetrahydropyran-3-yl]-2-[[6-(trifluoromethyl)-3-pyridyl]oxy]acetamide, or N-[(3R,6S)-6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]oxan-3-yl]-2-{[5-(trifluoromethyl)pyridin-3-yl]oxy}acetamide 21. The compound of any one of claims 1 to 20, wherein:

22. 22. A pharmaceutical composition comprising at least one compound according to any one of claims 1 to 21, or a pharma- ceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, together with a pharma- ceutically acceptable carrier, optionally in combination with one or more other biologically active compounds or pharmaceutical compositions.

23. 22. Use of a compound according to any one of claims 1 to 21 or a pharma- ceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof for the manufacture of a medicament.

24. Use of a compound according to any one of claims 1 to 21 or a pharma- ceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof for the manufacture of a medicament for the treatment or prevention of one or more diseases or disorders associated with the integrated stress response.

25. 22. Use of a compound according to any one of claims 1 to 21, or a pharma- ceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, for the manufacture of a medicament for the treatment or prevention of one or more diseases or disorders selected from the group consisting of leukodystrophies, intellectual disability syndromes, neurodegenerative diseases and disorders, neoplastic diseases, infectious diseases, inflammatory diseases, musculoskeletal diseases, metabolic diseases, ocular diseases, as well as one or more diseases selected from the group consisting of organ fibrosis, chronic and acute diseases of the liver, chronic and acute diseases of the lungs, chronic and acute diseases of the kidneys, myocardial infarction, cardiovascular diseases, arrhythmias, atherosclerosis, spinal cord injury, ischemic stroke, and neuropathic pain.

Citation Information

Patent Citations

  • Modulators of the eif2alpha pathway

    WO2014144952A2

  • Modulators of the integrated stress pathway

    WO2017193030A1

  • Modulators of the integrated stress pathway

    WO2017193034A1

  • Modulators of the integrated stress pathway

    WO2017193041A1

  • Modulators of the integrated stress pathway

    WO2017193063A1